{"entity":"gilead-sciences","id":"ent_gilead-sciences","name":"Gilead Sciences","wikidata":"Q663596","page":"https://asof.is/record/gilead-sciences","summary":"Gilead Sciences is an American biopharmaceutical company, headquartered in Foster City. It reported revenue of $29.44B for the period ended December 31, 2025.","title":"Gilead Sciences: revenue $29.44B","key_facts":[{"label":"Headquarters","value":"Foster City","claim":"clm_3AA77CFFBA18"},{"label":"Revenue","value":"$29.44B","recorded":"29,443,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_5E2D1C5DC1DC"},{"label":"Ticker","value":"GILD · Nasdaq","claim":"clm_ACCCAF058EE1"}],"faq":[{"question":"Where is Gilead Sciences headquartered?","answer":"Foster City."},{"question":"What is Gilead Sciences's revenue?","answer":"$29.44B for the period ended December 31, 2025."}],"as_of":null,"known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/gilead-sciences/headquarters","md":"https://asof.is/record/gilead-sciences/headquarters.md","json":"https://asof.is/v1/entities/gilead-sciences/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/gilead-sciences/revenue","md":"https://asof.is/record/gilead-sciences/revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/revenue"},{"predicate":"net_income","page":"https://asof.is/record/gilead-sciences/net_income","md":"https://asof.is/record/gilead-sciences/net_income.md","json":"https://asof.is/v1/entities/gilead-sciences/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/gilead-sciences/operating_income","md":"https://asof.is/record/gilead-sciences/operating_income.md","json":"https://asof.is/v1/entities/gilead-sciences/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/gilead-sciences/quarterly_revenue","md":"https://asof.is/record/gilead-sciences/quarterly_revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/quarterly_revenue"}],"products":[],"coverage":{"entity":"gilead-sciences","name":"Gilead Sciences","kind":"organization","sources":[{"source":"wikidata","item":"Q663596","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":882095,"ticker":"GILD","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":532,"open":20,"retracted":0,"first":"1994-02-14","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":51,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":25,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":532,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_3ADDE79BC725","predicate":"shares_outstanding","value":"1,240,338,614 shares","valid_from":"2026-10-23","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,338,614 shares\", as of 2026-10-23. Claim clm_3ADDE79BC725, https://asof.is/claim/clm_3ADDE79BC725, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_3ADDE79BC725","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_4B6581046BE2","predicate":"quarterly_net_income","value":"2,429,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,429,000,000 United States dollar\", as of 2026-09-30. Claim clm_4B6581046BE2, https://asof.is/claim/clm_4B6581046BE2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_4B6581046BE2","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_53C30342724D","predicate":"total_assets","value":"51,408,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 51,408,000,000 United States dollar\", as of 2026-09-30. Claim clm_53C30342724D, https://asof.is/claim/clm_53C30342724D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_53C30342724D","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_64E20B8C7E0A","predicate":"quarterly_revenue","value":"8,300,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 8,300,000,000 United States dollar\", as of 2026-09-30. Claim clm_64E20B8C7E0A, https://asof.is/claim/clm_64E20B8C7E0A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_64E20B8C7E0A","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_8490C244F9F5","predicate":"quarterly_operating_income","value":"3,462,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,462,000,000 United States dollar\", as of 2026-09-30. Claim clm_8490C244F9F5, https://asof.is/claim/clm_8490C244F9F5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_8490C244F9F5","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_F5C77DE07AFE","predicate":"total_equity","value":"13,040,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,040,000,000 United States dollar\", as of 2026-09-30. Claim clm_F5C77DE07AFE, https://asof.is/claim/clm_F5C77DE07AFE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_F5C77DE07AFE","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_87D3256ADA54","predicate":"shares_outstanding","value":"1,239,955,155 shares","valid_from":"2026-07-31","valid_to":"2026-10-23","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,239,955,155 shares\", as of 2026-07-31 (until 2026-10-23). Claim clm_87D3256ADA54, https://asof.is/claim/clm_87D3256ADA54, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_87D3256ADA54","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3ADDE79BC725","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_2C725370A4DF","predicate":"quarterly_revenue","value":"7,803,000,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,803,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_2C725370A4DF, https://asof.is/claim/clm_2C725370A4DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_2C725370A4DF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64E20B8C7E0A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_3745BC3CD67C","predicate":"total_equity","value":"11,829,000,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 11,829,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_3745BC3CD67C, https://asof.is/claim/clm_3745BC3CD67C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_3745BC3CD67C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F5C77DE07AFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_64932ED26A58","predicate":"total_assets","value":"49,362,000,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 49,362,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_64932ED26A58, https://asof.is/claim/clm_64932ED26A58, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_64932ED26A58","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_53C30342724D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_9D61925E21DF","predicate":"quarterly_net_income","value":"-10,496,000,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: -10,496,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_9D61925E21DF, https://asof.is/claim/clm_9D61925E21DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_9D61925E21DF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4B6581046BE2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_D52EB913CD0D","predicate":"quarterly_operating_income","value":"-10,394,000,000 United States dollar","valid_from":"2026-06-30","valid_to":"2026-09-30","published":"2026-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: -10,394,000,000 United States dollar\", as of 2026-06-30 (until 2026-09-30). Claim clm_D52EB913CD0D, https://asof.is/claim/clm_D52EB913CD0D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm.","url":"https://asof.is/claim/clm_D52EB913CD0D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8490C244F9F5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2026","published_at":"2026-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-06"}},{"id":"clm_453FCFB7AC1C","predicate":"shares_outstanding","value":"1,241,569,874 shares","valid_from":"2026-04-30","valid_to":"2026-07-31","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,241,569,874 shares\", as of 2026-04-30 (until 2026-07-31). Claim clm_453FCFB7AC1C, https://asof.is/claim/clm_453FCFB7AC1C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_453FCFB7AC1C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_87D3256ADA54","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_24FF1FC3A935","predicate":"quarterly_net_income","value":"2,021,000,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,021,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_24FF1FC3A935, https://asof.is/claim/clm_24FF1FC3A935, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_24FF1FC3A935","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9D61925E21DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_3305AD308056","predicate":"quarterly_operating_income","value":"2,586,000,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,586,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_3305AD308056, https://asof.is/claim/clm_3305AD308056, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_3305AD308056","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D52EB913CD0D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_5B00A751741D","predicate":"quarterly_revenue","value":"6,960,000,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,960,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_5B00A751741D, https://asof.is/claim/clm_5B00A751741D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_5B00A751741D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C725370A4DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_84AD5CE96A78","predicate":"total_assets","value":"56,278,000,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 56,278,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_84AD5CE96A78, https://asof.is/claim/clm_84AD5CE96A78, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_84AD5CE96A78","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64932ED26A58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_E5496920DE7C","predicate":"total_equity","value":"23,515,000,000 United States dollar","valid_from":"2026-03-31","valid_to":"2026-06-30","published":"2026-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 23,515,000,000 United States dollar\", as of 2026-03-31 (until 2026-06-30). Claim clm_E5496920DE7C, https://asof.is/claim/clm_E5496920DE7C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm.","url":"https://asof.is/claim/clm_E5496920DE7C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3745BC3CD67C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2026","published_at":"2026-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-05-07"}},{"id":"clm_E2DB5E0B53B4","predicate":"shares_outstanding","value":"1,241,420,528 shares","valid_from":"2026-02-13","valid_to":"2026-04-30","published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,241,420,528 shares\", as of 2026-02-13 (until 2026-04-30). Claim clm_E2DB5E0B53B4, https://asof.is/claim/clm_E2DB5E0B53B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_E2DB5E0B53B4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_453FCFB7AC1C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_06C160F8C3A5","predicate":"total_assets","value":"59,023,000,000 United States dollar","valid_from":"2025-12-31","valid_to":"2026-03-31","published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 59,023,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_06C160F8C3A5, https://asof.is/claim/clm_06C160F8C3A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_06C160F8C3A5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_84AD5CE96A78","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_075AC6F097D8","predicate":"net_income","value":"8,510,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 8,510,000,000 United States dollar\", as of 2025-12-31. Claim clm_075AC6F097D8, https://asof.is/claim/clm_075AC6F097D8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_075AC6F097D8","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_44AE227A69DA","predicate":"operating_income","value":"10,022,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 10,022,000,000 United States dollar\", as of 2025-12-31. Claim clm_44AE227A69DA, https://asof.is/claim/clm_44AE227A69DA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_44AE227A69DA","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_5E2D1C5DC1DC","predicate":"revenue","value":"29,443,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 29,443,000,000 United States dollar\", as of 2025-12-31. Claim clm_5E2D1C5DC1DC, https://asof.is/claim/clm_5E2D1C5DC1DC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_5E2D1C5DC1DC","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_994B784F55A6","predicate":"total_equity","value":"22,703,000,000 United States dollar","valid_from":"2025-12-31","valid_to":"2026-03-31","published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,703,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-31). Claim clm_994B784F55A6, https://asof.is/claim/clm_994B784F55A6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_994B784F55A6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E5496920DE7C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_5E452E3F3A54","predicate":"shares_outstanding","value":"1,240,679,623 shares","valid_from":"2025-10-31","valid_to":"2026-02-13","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,679,623 shares\", as of 2025-10-31 (until 2026-02-13). Claim clm_5E452E3F3A54, https://asof.is/claim/clm_5E452E3F3A54, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5E452E3F3A54","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2DB5E0B53B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_3A5203A42518","predicate":"quarterly_revenue","value":"7,769,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,769,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_3A5203A42518, https://asof.is/claim/clm_3A5203A42518, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_3A5203A42518","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B00A751741D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_5B9243C901AF","predicate":"total_assets","value":"58,533,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 58,533,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_5B9243C901AF, https://asof.is/claim/clm_5B9243C901AF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_5B9243C901AF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_06C160F8C3A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_8C716505DCB2","predicate":"quarterly_net_income","value":"3,052,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,052,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_8C716505DCB2, https://asof.is/claim/clm_8C716505DCB2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_8C716505DCB2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_24FF1FC3A935","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_B2A4004D2607","predicate":"total_equity","value":"21,540,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,540,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_B2A4004D2607, https://asof.is/claim/clm_B2A4004D2607, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_B2A4004D2607","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_994B784F55A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_E88E046C7258","predicate":"quarterly_operating_income","value":"3,327,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,327,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E88E046C7258, https://asof.is/claim/clm_E88E046C7258, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm.","url":"https://asof.is/claim/clm_E88E046C7258","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3305AD308056","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/0000882095-25-000047-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-07"}},{"id":"clm_9C3AF96BA25F","predicate":"shares_outstanding","value":"1,240,806,916 shares","valid_from":"2025-07-31","valid_to":"2025-10-31","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,806,916 shares\", as of 2025-07-31 (until 2025-10-31). Claim clm_9C3AF96BA25F, https://asof.is/claim/clm_9C3AF96BA25F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_9C3AF96BA25F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E452E3F3A54","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_126ADC7BE802","predicate":"quarterly_operating_income","value":"2,474,000,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,474,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_126ADC7BE802, https://asof.is/claim/clm_126ADC7BE802, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_126ADC7BE802","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E88E046C7258","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_96F4B471EBB0","predicate":"quarterly_net_income","value":"1,960,000,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,960,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_96F4B471EBB0, https://asof.is/claim/clm_96F4B471EBB0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_96F4B471EBB0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8C716505DCB2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_C86E2D68884A","predicate":"total_equity","value":"19,674,000,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 19,674,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_C86E2D68884A, https://asof.is/claim/clm_C86E2D68884A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_C86E2D68884A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B2A4004D2607","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_CE3CB21B31C4","predicate":"total_assets","value":"55,721,000,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 55,721,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_CE3CB21B31C4, https://asof.is/claim/clm_CE3CB21B31C4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_CE3CB21B31C4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B9243C901AF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_E0FB0CBAE021","predicate":"quarterly_revenue","value":"7,082,000,000 United States dollar","valid_from":"2025-06-30","valid_to":"2025-09-30","published":"2025-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,082,000,000 United States dollar\", as of 2025-06-30 (until 2025-09-30). Claim clm_E0FB0CBAE021, https://asof.is/claim/clm_E0FB0CBAE021, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm.","url":"https://asof.is/claim/clm_E0FB0CBAE021","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3A5203A42518","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/0000882095-25-000032-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2025","published_at":"2025-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2025, filed 2025-08-07"}},{"id":"clm_00BBB280CB5F","predicate":"shares_outstanding","value":"1,243,929,121 shares","valid_from":"2025-04-30","valid_to":"2025-07-31","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,243,929,121 shares\", as of 2025-04-30 (until 2025-07-31). Claim clm_00BBB280CB5F, https://asof.is/claim/clm_00BBB280CB5F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_00BBB280CB5F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9C3AF96BA25F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_096B626AF41F","predicate":"total_equity","value":"19,162,000,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 19,162,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_096B626AF41F, https://asof.is/claim/clm_096B626AF41F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_096B626AF41F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C86E2D68884A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_3A96D6D8CC27","predicate":"total_assets","value":"56,434,000,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 56,434,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_3A96D6D8CC27, https://asof.is/claim/clm_3A96D6D8CC27, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_3A96D6D8CC27","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CE3CB21B31C4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_4E922360F385","predicate":"quarterly_revenue","value":"6,667,000,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,667,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_4E922360F385, https://asof.is/claim/clm_4E922360F385, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_4E922360F385","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E0FB0CBAE021","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_AB2BA2625080","predicate":"quarterly_net_income","value":"1,315,000,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,315,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_AB2BA2625080, https://asof.is/claim/clm_AB2BA2625080, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_AB2BA2625080","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_96F4B471EBB0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_C7852A733EB8","predicate":"quarterly_operating_income","value":"2,237,000,000 United States dollar","valid_from":"2025-03-31","valid_to":"2025-06-30","published":"2025-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,237,000,000 United States dollar\", as of 2025-03-31 (until 2025-06-30). Claim clm_C7852A733EB8, https://asof.is/claim/clm_C7852A733EB8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm.","url":"https://asof.is/claim/clm_C7852A733EB8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_126ADC7BE802","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/0000882095-25-000012-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2025","published_at":"2025-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-07"}},{"id":"clm_2BEB2DBADF20","predicate":"shares_outstanding","value":"1,245,346,062 shares","valid_from":"2025-02-21","valid_to":"2025-04-30","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,245,346,062 shares\", as of 2025-02-21 (until 2025-04-30). Claim clm_2BEB2DBADF20, https://asof.is/claim/clm_2BEB2DBADF20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_2BEB2DBADF20","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_00BBB280CB5F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_39D2F7153DDD","predicate":"total_assets","value":"58,995,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-03-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 58,995,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_39D2F7153DDD, https://asof.is/claim/clm_39D2F7153DDD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_39D2F7153DDD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3A96D6D8CC27","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_4AF8C0C466F3","predicate":"total_equity","value":"19,330,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-03-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 19,330,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-31). Claim clm_4AF8C0C466F3, https://asof.is/claim/clm_4AF8C0C466F3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_4AF8C0C466F3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_096B626AF41F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_766F0DC2656D","predicate":"revenue","value":"28,754,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 28,754,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_766F0DC2656D, https://asof.is/claim/clm_766F0DC2656D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_766F0DC2656D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E2D1C5DC1DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_9D8D94D516C5","predicate":"operating_income","value":"1,662,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 1,662,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9D8D94D516C5, https://asof.is/claim/clm_9D8D94D516C5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_9D8D94D516C5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_44AE227A69DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_D66A9204BCB4","predicate":"net_income","value":"480,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 480,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_D66A9204BCB4, https://asof.is/claim/clm_D66A9204BCB4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm.","url":"https://asof.is/claim/clm_D66A9204BCB4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_075AC6F097D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-28"}},{"id":"clm_9DC09EC0227B","predicate":"shares_outstanding","value":"1,246,265,857 shares","valid_from":"2024-10-31","valid_to":"2025-02-21","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,246,265,857 shares\", as of 2024-10-31 (until 2025-02-21). Claim clm_9DC09EC0227B, https://asof.is/claim/clm_9DC09EC0227B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_9DC09EC0227B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2BEB2DBADF20","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_0F6781A0229E","predicate":"quarterly_net_income","value":"1,253,000,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,253,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_0F6781A0229E, https://asof.is/claim/clm_0F6781A0229E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_0F6781A0229E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AB2BA2625080","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_39562DEC6D14","predicate":"quarterly_revenue","value":"7,545,000,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,545,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_39562DEC6D14, https://asof.is/claim/clm_39562DEC6D14, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_39562DEC6D14","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4E922360F385","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_3E93DA6B7ADB","predicate":"total_assets","value":"54,525,000,000 United States dollar","valid_from":"2024-09-30","valid_to":"2024-12-31","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 54,525,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_3E93DA6B7ADB, https://asof.is/claim/clm_3E93DA6B7ADB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_3E93DA6B7ADB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_39D2F7153DDD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_7DD62F33711D","predicate":"quarterly_operating_income","value":"888,000,000 United States dollar","valid_from":"2024-09-30","valid_to":"2025-03-31","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 888,000,000 United States dollar\", as of 2024-09-30 (until 2025-03-31). Claim clm_7DD62F33711D, https://asof.is/claim/clm_7DD62F33711D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_7DD62F33711D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C7852A733EB8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_F14A51AD91E7","predicate":"total_equity","value":"18,475,000,000 United States dollar","valid_from":"2024-09-30","valid_to":"2024-12-31","published":"2024-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,475,000,000 United States dollar\", as of 2024-09-30 (until 2024-12-31). Claim clm_F14A51AD91E7, https://asof.is/claim/clm_F14A51AD91E7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm.","url":"https://asof.is/claim/clm_F14A51AD91E7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4AF8C0C466F3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/0000882095-24-000028-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2024","published_at":"2024-11-12T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-11-12"}},{"id":"clm_19FC99911C58","predicate":"shares_outstanding","value":"1,244,992,081 shares","valid_from":"2024-07-31","valid_to":"2024-10-31","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,244,992,081 shares\", as of 2024-07-31 (until 2024-10-31). Claim clm_19FC99911C58, https://asof.is/claim/clm_19FC99911C58, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_19FC99911C58","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9DC09EC0227B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_18BCC2F491A8","predicate":"quarterly_revenue","value":"6,954,000,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,954,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_18BCC2F491A8, https://asof.is/claim/clm_18BCC2F491A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_18BCC2F491A8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_39562DEC6D14","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_481B3C5AC3EB","predicate":"total_assets","value":"53,579,000,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 53,579,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_481B3C5AC3EB, https://asof.is/claim/clm_481B3C5AC3EB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_481B3C5AC3EB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3E93DA6B7ADB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_7098E59481B8","predicate":"quarterly_net_income","value":"1,614,000,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,614,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_7098E59481B8, https://asof.is/claim/clm_7098E59481B8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_7098E59481B8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0F6781A0229E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_7EE809D238E0","predicate":"total_equity","value":"18,281,000,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,281,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_7EE809D238E0, https://asof.is/claim/clm_7EE809D238E0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_7EE809D238E0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F14A51AD91E7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_AAD6E4F85DC7","predicate":"quarterly_operating_income","value":"2,644,000,000 United States dollar","valid_from":"2024-06-30","valid_to":"2024-09-30","published":"2024-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,644,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-30). Claim clm_AAD6E4F85DC7, https://asof.is/claim/clm_AAD6E4F85DC7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm.","url":"https://asof.is/claim/clm_AAD6E4F85DC7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7DD62F33711D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/0000882095-24-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2024","published_at":"2024-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-08"}},{"id":"clm_FA8BB7DB6F61","predicate":"shares_outstanding","value":"1,245,853,209 shares","valid_from":"2024-04-30","valid_to":"2024-07-31","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,245,853,209 shares\", as of 2024-04-30 (until 2024-07-31). Claim clm_FA8BB7DB6F61, https://asof.is/claim/clm_FA8BB7DB6F61, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_FA8BB7DB6F61","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_19FC99911C58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_08D7EEBC38FF","predicate":"quarterly_operating_income","value":"-4,322,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: -4,322,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_08D7EEBC38FF, https://asof.is/claim/clm_08D7EEBC38FF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_08D7EEBC38FF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AAD6E4F85DC7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_64A76DECC383","predicate":"total_equity","value":"17,539,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 17,539,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_64A76DECC383, https://asof.is/claim/clm_64A76DECC383, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_64A76DECC383","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7EE809D238E0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_A44E55A2C823","predicate":"quarterly_net_income","value":"-4,170,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: -4,170,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_A44E55A2C823, https://asof.is/claim/clm_A44E55A2C823, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_A44E55A2C823","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7098E59481B8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_B9F5256DAECB","predicate":"total_assets","value":"56,292,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 56,292,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_B9F5256DAECB, https://asof.is/claim/clm_B9F5256DAECB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_B9F5256DAECB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_481B3C5AC3EB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_C8DA722C3664","predicate":"quarterly_revenue","value":"6,686,000,000 United States dollar","valid_from":"2024-03-31","valid_to":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,686,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_C8DA722C3664, https://asof.is/claim/clm_C8DA722C3664, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm.","url":"https://asof.is/claim/clm_C8DA722C3664","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_18BCC2F491A8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/0000882095-24-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2024","published_at":"2024-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2024, filed 2024-05-08"}},{"id":"clm_692B7931D366","predicate":"shares_outstanding","value":"1,245,774,616 shares","valid_from":"2024-02-16","valid_to":"2024-04-30","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,245,774,616 shares\", as of 2024-02-16 (until 2024-04-30). Claim clm_692B7931D366, https://asof.is/claim/clm_692B7931D366, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_692B7931D366","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FA8BB7DB6F61","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_49E88DCFA6FB","predicate":"total_equity","value":"22,833,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-03-31","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,833,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_49E88DCFA6FB, https://asof.is/claim/clm_49E88DCFA6FB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_49E88DCFA6FB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64A76DECC383","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_4C71B25EAE57","predicate":"operating_income","value":"7,605,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 7,605,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_4C71B25EAE57, https://asof.is/claim/clm_4C71B25EAE57, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_4C71B25EAE57","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9D8D94D516C5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_9ED5DC7A3225","predicate":"net_income","value":"5,665,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 5,665,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_9ED5DC7A3225, https://asof.is/claim/clm_9ED5DC7A3225, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_9ED5DC7A3225","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D66A9204BCB4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_ABFE2CB3CF48","predicate":"revenue","value":"27,116,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-12-31","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 27,116,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_ABFE2CB3CF48, https://asof.is/claim/clm_ABFE2CB3CF48, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_ABFE2CB3CF48","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_766F0DC2656D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_E936AA9A1E59","predicate":"total_assets","value":"62,125,000,000 United States dollar","valid_from":"2023-12-31","valid_to":"2024-03-31","published":"2024-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,125,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_E936AA9A1E59, https://asof.is/claim/clm_E936AA9A1E59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm.","url":"https://asof.is/claim/clm_E936AA9A1E59","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B9F5256DAECB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2023","published_at":"2024-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-23"}},{"id":"clm_71C62A492740","predicate":"shares_outstanding","value":"1,246,041,895 shares","valid_from":"2023-10-31","valid_to":"2024-02-16","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,246,041,895 shares\", as of 2023-10-31 (until 2024-02-16). Claim clm_71C62A492740, https://asof.is/claim/clm_71C62A492740, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_71C62A492740","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_692B7931D366","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_51DCA48FA664","predicate":"quarterly_net_income","value":"2,180,000,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,180,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_51DCA48FA664, https://asof.is/claim/clm_51DCA48FA664, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_51DCA48FA664","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A44E55A2C823","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_56E2DDB08CBD","predicate":"quarterly_revenue","value":"7,051,000,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,051,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_56E2DDB08CBD, https://asof.is/claim/clm_56E2DDB08CBD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_56E2DDB08CBD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C8DA722C3664","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_C0C3423DA043","predicate":"quarterly_operating_income","value":"2,623,000,000 United States dollar","valid_from":"2023-09-30","valid_to":"2024-03-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,623,000,000 United States dollar\", as of 2023-09-30 (until 2024-03-31). Claim clm_C0C3423DA043, https://asof.is/claim/clm_C0C3423DA043, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_C0C3423DA043","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08D7EEBC38FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_ED56476EC42A","predicate":"total_equity","value":"22,314,000,000 United States dollar","valid_from":"2023-09-30","valid_to":"2023-12-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,314,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_ED56476EC42A, https://asof.is/claim/clm_ED56476EC42A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_ED56476EC42A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_49E88DCFA6FB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_FFEC37313BA6","predicate":"total_assets","value":"62,373,000,000 United States dollar","valid_from":"2023-09-30","valid_to":"2023-12-31","published":"2023-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,373,000,000 United States dollar\", as of 2023-09-30 (until 2023-12-31). Claim clm_FFEC37313BA6, https://asof.is/claim/clm_FFEC37313BA6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm.","url":"https://asof.is/claim/clm_FFEC37313BA6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E936AA9A1E59","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/0000882095-23-000031-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2023","published_at":"2023-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-07"}},{"id":"clm_C916C69CA972","predicate":"shares_outstanding","value":"1,246,014,353 shares","valid_from":"2023-07-31","valid_to":"2023-10-31","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,246,014,353 shares\", as of 2023-07-31 (until 2023-10-31). Claim clm_C916C69CA972, https://asof.is/claim/clm_C916C69CA972, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_C916C69CA972","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71C62A492740","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_1E9F69BD5141","predicate":"quarterly_revenue","value":"6,599,000,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,599,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_1E9F69BD5141, https://asof.is/claim/clm_1E9F69BD5141, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_1E9F69BD5141","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56E2DDB08CBD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_28DC5CDFDC6E","predicate":"quarterly_operating_income","value":"1,665,000,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,665,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_28DC5CDFDC6E, https://asof.is/claim/clm_28DC5CDFDC6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_28DC5CDFDC6E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C0C3423DA043","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_3CB17C366E6F","predicate":"total_assets","value":"62,337,000,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,337,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_3CB17C366E6F, https://asof.is/claim/clm_3CB17C366E6F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_3CB17C366E6F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FFEC37313BA6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_4FEA1639B883","predicate":"quarterly_net_income","value":"1,045,000,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,045,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_4FEA1639B883, https://asof.is/claim/clm_4FEA1639B883, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_4FEA1639B883","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_51DCA48FA664","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_7D955D2EB31A","predicate":"total_equity","value":"21,158,000,000 United States dollar","valid_from":"2023-06-30","valid_to":"2023-09-30","published":"2023-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,158,000,000 United States dollar\", as of 2023-06-30 (until 2023-09-30). Claim clm_7D955D2EB31A, https://asof.is/claim/clm_7D955D2EB31A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm.","url":"https://asof.is/claim/clm_7D955D2EB31A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ED56476EC42A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/0000882095-23-000025-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2023","published_at":"2023-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-04"}},{"id":"clm_59F0A1944F37","predicate":"shares_outstanding","value":"1,247,352,689 shares","valid_from":"2023-04-28","valid_to":"2023-07-31","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,247,352,689 shares\", as of 2023-04-28 (until 2023-07-31). Claim clm_59F0A1944F37, https://asof.is/claim/clm_59F0A1944F37, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_59F0A1944F37","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C916C69CA972","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_13A4177E72E9","predicate":"total_assets","value":"61,876,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 61,876,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_13A4177E72E9, https://asof.is/claim/clm_13A4177E72E9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_13A4177E72E9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3CB17C366E6F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_2124B66E70B5","predicate":"quarterly_revenue","value":"6,352,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,352,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_2124B66E70B5, https://asof.is/claim/clm_2124B66E70B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_2124B66E70B5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E9F69BD5141","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_3745B13B8F94","predicate":"quarterly_operating_income","value":"1,705,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,705,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_3745B13B8F94, https://asof.is/claim/clm_3745B13B8F94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_3745B13B8F94","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_28DC5CDFDC6E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_C75019B7A8F6","predicate":"total_equity","value":"20,997,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,997,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_C75019B7A8F6, https://asof.is/claim/clm_C75019B7A8F6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_C75019B7A8F6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7D955D2EB31A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_EC8C36049672","predicate":"quarterly_net_income","value":"1,010,000,000 United States dollar","valid_from":"2023-03-31","valid_to":"2023-06-30","published":"2023-05-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,010,000,000 United States dollar\", as of 2023-03-31 (until 2023-06-30). Claim clm_EC8C36049672, https://asof.is/claim/clm_EC8C36049672, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm.","url":"https://asof.is/claim/clm_EC8C36049672","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4FEA1639B883","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/0000882095-23-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2023","published_at":"2023-05-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-03"}},{"id":"clm_0E722F0B4CD6","predicate":"shares_outstanding","value":"1,247,105,154 shares","valid_from":"2023-02-17","valid_to":"2023-04-28","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,247,105,154 shares\", as of 2023-02-17 (until 2023-04-28). Claim clm_0E722F0B4CD6, https://asof.is/claim/clm_0E722F0B4CD6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_0E722F0B4CD6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_59F0A1944F37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_1850599904BE","predicate":"operating_income","value":"7,330,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 7,330,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_1850599904BE, https://asof.is/claim/clm_1850599904BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_1850599904BE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4C71B25EAE57","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_46F0FD922BCD","predicate":"total_assets","value":"63,171,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-03-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 63,171,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_46F0FD922BCD, https://asof.is/claim/clm_46F0FD922BCD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_46F0FD922BCD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_13A4177E72E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_5E875C84FD17","predicate":"net_income","value":"4,592,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 4,592,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_5E875C84FD17, https://asof.is/claim/clm_5E875C84FD17, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_5E875C84FD17","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9ED5DC7A3225","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_63D857B5C382","predicate":"revenue","value":"27,281,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-12-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 27,281,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_63D857B5C382, https://asof.is/claim/clm_63D857B5C382, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_63D857B5C382","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ABFE2CB3CF48","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_7B68B20F3E17","predicate":"cash_and_equivalents","value":"5,412,000,000 United States dollar","valid_from":"2022-12-31","valid_to":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,412,000,000 United States dollar\", as of 2022-12-31. Claim clm_7B68B20F3E17, https://asof.is/claim/clm_7B68B20F3E17, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_7B68B20F3E17","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_9F042AE98A38","predicate":"total_equity","value":"21,240,000,000 United States dollar","valid_from":"2022-12-31","valid_to":"2023-03-31","published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,240,000,000 United States dollar\", as of 2022-12-31 (until 2023-03-31). Claim clm_9F042AE98A38, https://asof.is/claim/clm_9F042AE98A38, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_9F042AE98A38","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C75019B7A8F6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_66357F3D3F64","predicate":"shares_outstanding","value":"1,254,243,845 shares","valid_from":"2022-10-31","valid_to":"2023-02-17","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,254,243,845 shares\", as of 2022-10-31 (until 2023-02-17). Claim clm_66357F3D3F64, https://asof.is/claim/clm_66357F3D3F64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_66357F3D3F64","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E722F0B4CD6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_2FD264F5993C","predicate":"total_equity","value":"21,081,000,000 United States dollar","valid_from":"2022-09-30","valid_to":"2022-12-31","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,081,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_2FD264F5993C, https://asof.is/claim/clm_2FD264F5993C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_2FD264F5993C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9F042AE98A38","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_AFE437797FF5","predicate":"quarterly_operating_income","value":"2,837,000,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,837,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_AFE437797FF5, https://asof.is/claim/clm_AFE437797FF5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_AFE437797FF5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3745B13B8F94","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_D40D37E7611A","predicate":"total_assets","value":"62,557,000,000 United States dollar","valid_from":"2022-09-30","valid_to":"2022-12-31","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,557,000,000 United States dollar\", as of 2022-09-30 (until 2022-12-31). Claim clm_D40D37E7611A, https://asof.is/claim/clm_D40D37E7611A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_D40D37E7611A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46F0FD922BCD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_FB8452B2152F","predicate":"quarterly_revenue","value":"7,042,000,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,042,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_FB8452B2152F, https://asof.is/claim/clm_FB8452B2152F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_FB8452B2152F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2124B66E70B5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_FE7757875B59","predicate":"quarterly_net_income","value":"1,789,000,000 United States dollar","valid_from":"2022-09-30","valid_to":"2023-03-31","published":"2022-11-02","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,789,000,000 United States dollar\", as of 2022-09-30 (until 2023-03-31). Claim clm_FE7757875B59, https://asof.is/claim/clm_FE7757875B59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm.","url":"https://asof.is/claim/clm_FE7757875B59","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EC8C36049672","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000027/0000882095-22-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2022","published_at":"2022-11-02T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-02"}},{"id":"clm_4E0A628F0E89","predicate":"shares_outstanding","value":"1,253,367,394 shares","valid_from":"2022-07-29","valid_to":"2022-10-31","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,253,367,394 shares\", as of 2022-07-29 (until 2022-10-31). Claim clm_4E0A628F0E89, https://asof.is/claim/clm_4E0A628F0E89, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_4E0A628F0E89","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_66357F3D3F64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_8373F49F9F4A","predicate":"quarterly_operating_income","value":"2,029,000,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,029,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_8373F49F9F4A, https://asof.is/claim/clm_8373F49F9F4A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_8373F49F9F4A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AFE437797FF5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_BCC35251681F","predicate":"quarterly_net_income","value":"1,144,000,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,144,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_BCC35251681F, https://asof.is/claim/clm_BCC35251681F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_BCC35251681F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FE7757875B59","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_C2489C029177","predicate":"total_equity","value":"20,236,000,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,236,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_C2489C029177, https://asof.is/claim/clm_C2489C029177, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_C2489C029177","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2FD264F5993C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_D9A309C9ADEC","predicate":"total_assets","value":"62,870,000,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,870,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_D9A309C9ADEC, https://asof.is/claim/clm_D9A309C9ADEC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_D9A309C9ADEC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D40D37E7611A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_DAC30FE4D631","predicate":"quarterly_revenue","value":"6,260,000,000 United States dollar","valid_from":"2022-06-30","valid_to":"2022-09-30","published":"2022-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,260,000,000 United States dollar\", as of 2022-06-30 (until 2022-09-30). Claim clm_DAC30FE4D631, https://asof.is/claim/clm_DAC30FE4D631, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm.","url":"https://asof.is/claim/clm_DAC30FE4D631","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FB8452B2152F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000019/0000882095-22-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2022","published_at":"2022-08-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2022, filed 2022-08-08"}},{"id":"clm_2508959DB71E","predicate":"shares_outstanding","value":"1,254,313,448 shares","valid_from":"2022-04-29","valid_to":"2022-07-29","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,254,313,448 shares\", as of 2022-04-29 (until 2022-07-29). Claim clm_2508959DB71E, https://asof.is/claim/clm_2508959DB71E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_2508959DB71E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4E0A628F0E89","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_04055A7D0B36","predicate":"total_equity","value":"19,927,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 19,927,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_04055A7D0B36, https://asof.is/claim/clm_04055A7D0B36, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_04055A7D0B36","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C2489C029177","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_43A0A904B6D6","predicate":"quarterly_revenue","value":"6,590,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,590,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_43A0A904B6D6, https://asof.is/claim/clm_43A0A904B6D6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_43A0A904B6D6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DAC30FE4D631","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_8BA86AE5EFB2","predicate":"quarterly_operating_income","value":"197,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 197,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_8BA86AE5EFB2, https://asof.is/claim/clm_8BA86AE5EFB2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_8BA86AE5EFB2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8373F49F9F4A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_B63753C50038","predicate":"quarterly_net_income","value":"19,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 19,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_B63753C50038, https://asof.is/claim/clm_B63753C50038, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_B63753C50038","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BCC35251681F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_DEF79188C6E2","predicate":"total_assets","value":"63,080,000,000 United States dollar","valid_from":"2022-03-31","valid_to":"2022-06-30","published":"2022-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 63,080,000,000 United States dollar\", as of 2022-03-31 (until 2022-06-30). Claim clm_DEF79188C6E2, https://asof.is/claim/clm_DEF79188C6E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm.","url":"https://asof.is/claim/clm_DEF79188C6E2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D9A309C9ADEC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000013/0000882095-22-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2022","published_at":"2022-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-04"}},{"id":"clm_2AF6C073F7F8","predicate":"shares_outstanding","value":"1,253,886,724 shares","valid_from":"2022-02-18","valid_to":"2022-04-29","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,253,886,724 shares\", as of 2022-02-18 (until 2022-04-29). Claim clm_2AF6C073F7F8, https://asof.is/claim/clm_2AF6C073F7F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_2AF6C073F7F8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2508959DB71E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_081201354DBD","predicate":"total_assets","value":"67,952,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-03-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 67,952,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_081201354DBD, https://asof.is/claim/clm_081201354DBD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_081201354DBD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DEF79188C6E2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_64A5CDC8438B","predicate":"cash_and_equivalents","value":"5,338,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,338,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_64A5CDC8438B, https://asof.is/claim/clm_64A5CDC8438B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_64A5CDC8438B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7B68B20F3E17","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_747FB329FEC7","predicate":"total_equity","value":"21,069,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-03-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,069,000,000 United States dollar\", as of 2021-12-31 (until 2022-03-31). Claim clm_747FB329FEC7, https://asof.is/claim/clm_747FB329FEC7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_747FB329FEC7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_04055A7D0B36","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_C45AC1BEB9A4","predicate":"net_income","value":"6,225,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 6,225,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_C45AC1BEB9A4, https://asof.is/claim/clm_C45AC1BEB9A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_C45AC1BEB9A4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E875C84FD17","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_C535F4EBB92C","predicate":"operating_income","value":"9,918,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 9,918,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_C535F4EBB92C, https://asof.is/claim/clm_C535F4EBB92C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_C535F4EBB92C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1850599904BE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_D6C1A036D30A","predicate":"revenue","value":"27,305,000,000 United States dollar","valid_from":"2021-12-31","valid_to":"2022-12-31","published":"2022-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 27,305,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_D6C1A036D30A, https://asof.is/claim/clm_D6C1A036D30A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm.","url":"https://asof.is/claim/clm_D6C1A036D30A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_63D857B5C382","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2021","published_at":"2022-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2021, filed 2022-02-23"}},{"id":"clm_35E68D12C487","predicate":"shares_outstanding","value":"1,254,383,522 shares","valid_from":"2021-10-29","valid_to":"2022-02-18","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,254,383,522 shares\", as of 2021-10-29 (until 2022-02-18). Claim clm_35E68D12C487, https://asof.is/claim/clm_35E68D12C487, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_35E68D12C487","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2AF6C073F7F8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_19619F47A018","predicate":"quarterly_revenue","value":"7,421,000,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,421,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_19619F47A018, https://asof.is/claim/clm_19619F47A018, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_19619F47A018","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_43A0A904B6D6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_1FFACD8ACFEC","predicate":"total_assets","value":"67,098,000,000 United States dollar","valid_from":"2021-09-30","valid_to":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 67,098,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_1FFACD8ACFEC, https://asof.is/claim/clm_1FFACD8ACFEC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_1FFACD8ACFEC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_081201354DBD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_25811D4BA2CF","predicate":"quarterly_net_income","value":"2,592,000,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,592,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_25811D4BA2CF, https://asof.is/claim/clm_25811D4BA2CF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_25811D4BA2CF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B63753C50038","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_2D8E14863B08","predicate":"total_equity","value":"21,470,000,000 United States dollar","valid_from":"2021-09-30","valid_to":"2021-12-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,470,000,000 United States dollar\", as of 2021-09-30 (until 2021-12-31). Claim clm_2D8E14863B08, https://asof.is/claim/clm_2D8E14863B08, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_2D8E14863B08","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_747FB329FEC7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_7DE0B9D2BDB0","predicate":"quarterly_operating_income","value":"3,842,000,000 United States dollar","valid_from":"2021-09-30","valid_to":"2022-03-31","published":"2021-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,842,000,000 United States dollar\", as of 2021-09-30 (until 2022-03-31). Claim clm_7DE0B9D2BDB0, https://asof.is/claim/clm_7DE0B9D2BDB0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm.","url":"https://asof.is/claim/clm_7DE0B9D2BDB0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8BA86AE5EFB2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000029/0000882095-21-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2021","published_at":"2021-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-03"}},{"id":"clm_F700D9C680AB","predicate":"shares_outstanding","value":"1,253,809,440 shares","valid_from":"2021-07-30","valid_to":"2021-10-29","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,253,809,440 shares\", as of 2021-07-30 (until 2021-10-29). Claim clm_F700D9C680AB, https://asof.is/claim/clm_F700D9C680AB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_F700D9C680AB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_35E68D12C487","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_1E4391435E59","predicate":"quarterly_net_income","value":"1,522,000,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,522,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_1E4391435E59, https://asof.is/claim/clm_1E4391435E59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_1E4391435E59","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_25811D4BA2CF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_217A2416EF41","predicate":"total_equity","value":"19,703,000,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 19,703,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_217A2416EF41, https://asof.is/claim/clm_217A2416EF41, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_217A2416EF41","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2D8E14863B08","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_62C48A7DBB68","predicate":"quarterly_revenue","value":"6,217,000,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,217,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_62C48A7DBB68, https://asof.is/claim/clm_62C48A7DBB68, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_62C48A7DBB68","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_19619F47A018","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_AE9CA8B5FEB8","predicate":"total_assets","value":"67,984,000,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 67,984,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_AE9CA8B5FEB8, https://asof.is/claim/clm_AE9CA8B5FEB8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_AE9CA8B5FEB8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1FFACD8ACFEC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_AF92F29DEEC7","predicate":"quarterly_operating_income","value":"2,246,000,000 United States dollar","valid_from":"2021-06-30","valid_to":"2021-09-30","published":"2021-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,246,000,000 United States dollar\", as of 2021-06-30 (until 2021-09-30). Claim clm_AF92F29DEEC7, https://asof.is/claim/clm_AF92F29DEEC7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm.","url":"https://asof.is/claim/clm_AF92F29DEEC7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7DE0B9D2BDB0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000021/0000882095-21-000021-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2021","published_at":"2021-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-05"}},{"id":"clm_DB0A15F124B7","predicate":"shares_outstanding","value":"1,254,178,166 shares","valid_from":"2021-04-30","valid_to":"2021-07-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,254,178,166 shares\", as of 2021-04-30 (until 2021-07-30). Claim clm_DB0A15F124B7, https://asof.is/claim/clm_DB0A15F124B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_DB0A15F124B7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F700D9C680AB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_14A44F8EE7B7","predicate":"total_assets","value":"67,492,000,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 67,492,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_14A44F8EE7B7, https://asof.is/claim/clm_14A44F8EE7B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_14A44F8EE7B7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AE9CA8B5FEB8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_19A157E5E599","predicate":"total_equity","value":"18,952,000,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,952,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_19A157E5E599, https://asof.is/claim/clm_19A157E5E599, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_19A157E5E599","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_217A2416EF41","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_1B217E0A1C39","predicate":"quarterly_operating_income","value":"2,890,000,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,890,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_1B217E0A1C39, https://asof.is/claim/clm_1B217E0A1C39, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_1B217E0A1C39","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AF92F29DEEC7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_4C823B39A502","predicate":"quarterly_net_income","value":"1,729,000,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,729,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_4C823B39A502, https://asof.is/claim/clm_4C823B39A502, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_4C823B39A502","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E4391435E59","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_C2B19AF3DC0B","predicate":"quarterly_revenue","value":"6,423,000,000 United States dollar","valid_from":"2021-03-31","valid_to":"2021-06-30","published":"2021-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,423,000,000 United States dollar\", as of 2021-03-31 (until 2021-06-30). Claim clm_C2B19AF3DC0B, https://asof.is/claim/clm_C2B19AF3DC0B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm.","url":"https://asof.is/claim/clm_C2B19AF3DC0B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_62C48A7DBB68","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000013/0000882095-21-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2021","published_at":"2021-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2021, filed 2021-05-06"}},{"id":"clm_9574C3BBD817","predicate":"shares_outstanding","value":"1,256,593,156 shares","valid_from":"2021-02-18","valid_to":"2021-04-30","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,256,593,156 shares\", as of 2021-02-18 (until 2021-04-30). Claim clm_9574C3BBD817, https://asof.is/claim/clm_9574C3BBD817, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_9574C3BBD817","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DB0A15F124B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_1E9CDD4692C6","predicate":"total_equity","value":"18,202,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-03-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,202,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_1E9CDD4692C6, https://asof.is/claim/clm_1E9CDD4692C6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_1E9CDD4692C6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_19A157E5E599","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_371075143050","predicate":"operating_income","value":"4,071,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 4,071,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_371075143050, https://asof.is/claim/clm_371075143050, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_371075143050","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C535F4EBB92C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_9D3C6259FA1C","predicate":"cash_and_equivalents","value":"5,997,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,997,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_9D3C6259FA1C, https://asof.is/claim/clm_9D3C6259FA1C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_9D3C6259FA1C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64A5CDC8438B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_BAAD13DDEE58","predicate":"net_income","value":"123,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 123,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_BAAD13DDEE58, https://asof.is/claim/clm_BAAD13DDEE58, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_BAAD13DDEE58","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C45AC1BEB9A4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_BCA2F683C1DE","predicate":"revenue","value":"24,689,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-12-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 24,689,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_BCA2F683C1DE, https://asof.is/claim/clm_BCA2F683C1DE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_BCA2F683C1DE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D6C1A036D30A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_F6DE64E9963C","predicate":"total_assets","value":"68,407,000,000 United States dollar","valid_from":"2020-12-31","valid_to":"2021-03-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 68,407,000,000 United States dollar\", as of 2020-12-31 (until 2021-03-31). Claim clm_F6DE64E9963C, https://asof.is/claim/clm_F6DE64E9963C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm.","url":"https://asof.is/claim/clm_F6DE64E9963C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_14A44F8EE7B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2020","published_at":"2021-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-25"}},{"id":"clm_CBA1F6B8ED24","predicate":"shares_outstanding","value":"1,253,528,149 shares","valid_from":"2020-10-30","valid_to":"2021-02-18","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,253,528,149 shares\", as of 2020-10-30 (until 2021-02-18). Claim clm_CBA1F6B8ED24, https://asof.is/claim/clm_CBA1F6B8ED24, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_CBA1F6B8ED24","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9574C3BBD817","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_2831E2519483","predicate":"total_assets","value":"60,878,000,000 United States dollar","valid_from":"2020-09-30","valid_to":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 60,878,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_2831E2519483, https://asof.is/claim/clm_2831E2519483, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_2831E2519483","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F6DE64E9963C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_33B63987BE41","predicate":"total_equity","value":"17,445,000,000 United States dollar","valid_from":"2020-09-30","valid_to":"2020-12-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 17,445,000,000 United States dollar\", as of 2020-09-30 (until 2020-12-31). Claim clm_33B63987BE41, https://asof.is/claim/clm_33B63987BE41, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_33B63987BE41","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E9CDD4692C6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_5E833A6DE889","predicate":"quarterly_revenue","value":"6,577,000,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,577,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_5E833A6DE889, https://asof.is/claim/clm_5E833A6DE889, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_5E833A6DE889","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C2B19AF3DC0B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_6D1C97E6B8EE","predicate":"quarterly_operating_income","value":"2,001,000,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,001,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_6D1C97E6B8EE, https://asof.is/claim/clm_6D1C97E6B8EE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_6D1C97E6B8EE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B217E0A1C39","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_7F3A59E84FB2","predicate":"quarterly_net_income","value":"360,000,000 United States dollar","valid_from":"2020-09-30","valid_to":"2021-03-31","published":"2020-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 360,000,000 United States dollar\", as of 2020-09-30 (until 2021-03-31). Claim clm_7F3A59E84FB2, https://asof.is/claim/clm_7F3A59E84FB2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm.","url":"https://asof.is/claim/clm_7F3A59E84FB2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4C823B39A502","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000027/0000882095-20-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2020","published_at":"2020-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-04"}},{"id":"clm_F01E60E4BBB6","predicate":"shares_outstanding","value":"1,253,724,370 shares","valid_from":"2020-07-31","valid_to":"2020-10-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,253,724,370 shares\", as of 2020-07-31 (until 2020-10-30). Claim clm_F01E60E4BBB6, https://asof.is/claim/clm_F01E60E4BBB6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_F01E60E4BBB6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CBA1F6B8ED24","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_1ACA29BAAAE0","predicate":"quarterly_revenue","value":"5,143,000,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,143,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_1ACA29BAAAE0, https://asof.is/claim/clm_1ACA29BAAAE0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_1ACA29BAAAE0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5E833A6DE889","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_3E90EE434813","predicate":"quarterly_operating_income","value":"-2,983,000,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: -2,983,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_3E90EE434813, https://asof.is/claim/clm_3E90EE434813, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_3E90EE434813","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D1C97E6B8EE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_48BA86C58B18","predicate":"total_equity","value":"18,027,000,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,027,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_48BA86C58B18, https://asof.is/claim/clm_48BA86C58B18, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_48BA86C58B18","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_33B63987BE41","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_861B89AF3C43","predicate":"quarterly_net_income","value":"-3,339,000,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: -3,339,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_861B89AF3C43, https://asof.is/claim/clm_861B89AF3C43, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_861B89AF3C43","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F3A59E84FB2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_A09500CBC958","predicate":"total_assets","value":"55,934,000,000 United States dollar","valid_from":"2020-06-30","valid_to":"2020-09-30","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 55,934,000,000 United States dollar\", as of 2020-06-30 (until 2020-09-30). Claim clm_A09500CBC958, https://asof.is/claim/clm_A09500CBC958, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm.","url":"https://asof.is/claim/clm_A09500CBC958","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2831E2519483","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000019/0000882095-20-000019-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2020","published_at":"2020-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-08-06"}},{"id":"clm_422B393AA321","predicate":"shares_outstanding","value":"1,254,373,400 shares","valid_from":"2020-04-30","valid_to":"2020-07-31","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,254,373,400 shares\", as of 2020-04-30 (until 2020-07-31). Claim clm_422B393AA321, https://asof.is/claim/clm_422B393AA321, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_422B393AA321","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F01E60E4BBB6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_46B555B900FF","predicate":"quarterly_research_and_development","value":"1,101,000,000 United States dollar","valid_from":"2020-03-31","valid_to":null,"published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,101,000,000 United States dollar\", as of 2020-03-31. Claim clm_46B555B900FF, https://asof.is/claim/clm_46B555B900FF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_46B555B900FF","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_6E06E702C841","predicate":"quarterly_revenue","value":"5,548,000,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,548,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_6E06E702C841, https://asof.is/claim/clm_6E06E702C841, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_6E06E702C841","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1ACA29BAAAE0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_8CDEFAE4FDAA","predicate":"total_assets","value":"59,741,000,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 59,741,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_8CDEFAE4FDAA, https://asof.is/claim/clm_8CDEFAE4FDAA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_8CDEFAE4FDAA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A09500CBC958","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_C484B0E46708","predicate":"quarterly_operating_income","value":"2,402,000,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,402,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_C484B0E46708, https://asof.is/claim/clm_C484B0E46708, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_C484B0E46708","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3E90EE434813","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_E1D334CD57DC","predicate":"total_equity","value":"22,067,000,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,067,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_E1D334CD57DC, https://asof.is/claim/clm_E1D334CD57DC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_E1D334CD57DC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_48BA86C58B18","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_E6DF670C65F1","predicate":"quarterly_net_income","value":"1,551,000,000 United States dollar","valid_from":"2020-03-31","valid_to":"2020-06-30","published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,551,000,000 United States dollar\", as of 2020-03-31 (until 2020-06-30). Claim clm_E6DF670C65F1, https://asof.is/claim/clm_E6DF670C65F1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_E6DF670C65F1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_861B89AF3C43","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_12B84D5C13CF","predicate":"shares_outstanding","value":"1,263,636,656 shares","valid_from":"2020-02-18","valid_to":"2020-04-30","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,263,636,656 shares\", as of 2020-02-18 (until 2020-04-30). Claim clm_12B84D5C13CF, https://asof.is/claim/clm_12B84D5C13CF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_12B84D5C13CF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_422B393AA321","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_02108FE6FC36","predicate":"total_assets","value":"61,627,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-03-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 61,627,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_02108FE6FC36, https://asof.is/claim/clm_02108FE6FC36, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_02108FE6FC36","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8CDEFAE4FDAA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_023882052B6B","predicate":"operating_income","value":"4,287,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 4,287,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_023882052B6B, https://asof.is/claim/clm_023882052B6B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_023882052B6B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_371075143050","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_0E1C61435482","predicate":"cash_and_equivalents","value":"11,631,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 11,631,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_0E1C61435482, https://asof.is/claim/clm_0E1C61435482, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_0E1C61435482","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9D3C6259FA1C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_43120E77E428","predicate":"revenue","value":"22,449,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 22,449,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_43120E77E428, https://asof.is/claim/clm_43120E77E428, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_43120E77E428","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BCA2F683C1DE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_82B29CB8F647","predicate":"total_equity","value":"22,525,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-03-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,525,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-31). Claim clm_82B29CB8F647, https://asof.is/claim/clm_82B29CB8F647, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_82B29CB8F647","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E1D334CD57DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_E9B23117B9AF","predicate":"net_income","value":"5,386,000,000 United States dollar","valid_from":"2019-12-31","valid_to":"2020-12-31","published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 5,386,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_E9B23117B9AF, https://asof.is/claim/clm_E9B23117B9AF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_E9B23117B9AF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BAAD13DDEE58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_EF2F795524C5","predicate":"research_and_development","value":"9,106,000,000 United States dollar","valid_from":"2019-12-31","valid_to":null,"published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 9,106,000,000 United States dollar\", as of 2019-12-31. Claim clm_EF2F795524C5, https://asof.is/claim/clm_EF2F795524C5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_EF2F795524C5","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_6B1F9AD01EEC","predicate":"shares_outstanding","value":"1,265,145,612 shares","valid_from":"2019-10-29","valid_to":"2020-02-18","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,265,145,612 shares\", as of 2019-10-29 (until 2020-02-18). Claim clm_6B1F9AD01EEC, https://asof.is/claim/clm_6B1F9AD01EEC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_6B1F9AD01EEC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12B84D5C13CF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_1E58DF837507","predicate":"quarterly_net_income","value":"-1,165,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: -1,165,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_1E58DF837507, https://asof.is/claim/clm_1E58DF837507, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_1E58DF837507","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E6DF670C65F1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_2BA275917569","predicate":"quarterly_research_and_development","value":"4,990,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 4,990,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_2BA275917569, https://asof.is/claim/clm_2BA275917569, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_2BA275917569","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46B555B900FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_30E506D439CD","predicate":"total_equity","value":"20,604,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2019-12-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,604,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_30E506D439CD, https://asof.is/claim/clm_30E506D439CD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_30E506D439CD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_82B29CB8F647","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_C8C1E348455A","predicate":"quarterly_operating_income","value":"-1,473,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: -1,473,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_C8C1E348455A, https://asof.is/claim/clm_C8C1E348455A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_C8C1E348455A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C484B0E46708","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_D7E17CBC3EB3","predicate":"total_assets","value":"59,146,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2019-12-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 59,146,000,000 United States dollar\", as of 2019-09-30 (until 2019-12-31). Claim clm_D7E17CBC3EB3, https://asof.is/claim/clm_D7E17CBC3EB3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_D7E17CBC3EB3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_02108FE6FC36","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_EF8E4AC29278","predicate":"quarterly_revenue","value":"5,604,000,000 United States dollar","valid_from":"2019-09-30","valid_to":"2020-03-31","published":"2019-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,604,000,000 United States dollar\", as of 2019-09-30 (until 2020-03-31). Claim clm_EF8E4AC29278, https://asof.is/claim/clm_EF8E4AC29278, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm.","url":"https://asof.is/claim/clm_EF8E4AC29278","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6E06E702C841","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000027/0000882095-19-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2019","published_at":"2019-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2019, filed 2019-11-05"}},{"id":"clm_A594D1759806","predicate":"shares_outstanding","value":"1,266,455,481 shares","valid_from":"2019-07-30","valid_to":"2019-10-29","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,266,455,481 shares\", as of 2019-07-30 (until 2019-10-29). Claim clm_A594D1759806, https://asof.is/claim/clm_A594D1759806, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_A594D1759806","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6B1F9AD01EEC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_56C675C78488","predicate":"quarterly_research_and_development","value":"1,160,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,160,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_56C675C78488, https://asof.is/claim/clm_56C675C78488, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_56C675C78488","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2BA275917569","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_57A874E5A2DF","predicate":"quarterly_revenue","value":"5,685,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,685,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_57A874E5A2DF, https://asof.is/claim/clm_57A874E5A2DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_57A874E5A2DF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF8E4AC29278","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_6CBC8FA47C02","predicate":"quarterly_operating_income","value":"2,430,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,430,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_6CBC8FA47C02, https://asof.is/claim/clm_6CBC8FA47C02, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_6CBC8FA47C02","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C8C1E348455A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_6F4EA3581211","predicate":"cash_and_equivalents","value":"11,240,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-12-31","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 11,240,000,000 United States dollar\", as of 2019-06-30 (until 2019-12-31). Claim clm_6F4EA3581211, https://asof.is/claim/clm_6F4EA3581211, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_6F4EA3581211","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0E1C61435482","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_930129505748","predicate":"quarterly_net_income","value":"1,880,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,880,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_930129505748, https://asof.is/claim/clm_930129505748, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_930129505748","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1E58DF837507","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_9BD72894A2FA","predicate":"total_equity","value":"22,616,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,616,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_9BD72894A2FA, https://asof.is/claim/clm_9BD72894A2FA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_9BD72894A2FA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30E506D439CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_C442F5426531","predicate":"total_assets","value":"63,210,000,000 United States dollar","valid_from":"2019-06-30","valid_to":"2019-09-30","published":"2019-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 63,210,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-30). Claim clm_C442F5426531, https://asof.is/claim/clm_C442F5426531, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm.","url":"https://asof.is/claim/clm_C442F5426531","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D7E17CBC3EB3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000020/0000882095-19-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2019","published_at":"2019-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-06"}},{"id":"clm_55FF6D3BF284","predicate":"shares_outstanding","value":"1,271,554,672 shares","valid_from":"2019-04-30","valid_to":"2019-07-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,271,554,672 shares\", as of 2019-04-30 (until 2019-07-30). Claim clm_55FF6D3BF284, https://asof.is/claim/clm_55FF6D3BF284, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_55FF6D3BF284","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A594D1759806","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_304B07F7B38F","predicate":"quarterly_operating_income","value":"2,237,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,237,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_304B07F7B38F, https://asof.is/claim/clm_304B07F7B38F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_304B07F7B38F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6CBC8FA47C02","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_427FE77026B1","predicate":"total_equity","value":"21,951,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,951,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_427FE77026B1, https://asof.is/claim/clm_427FE77026B1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_427FE77026B1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9BD72894A2FA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_7C0CBF1B6C32","predicate":"total_assets","value":"62,837,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 62,837,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_7C0CBF1B6C32, https://asof.is/claim/clm_7C0CBF1B6C32, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_7C0CBF1B6C32","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C442F5426531","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_981215B6D1DE","predicate":"quarterly_net_income","value":"1,975,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,975,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_981215B6D1DE, https://asof.is/claim/clm_981215B6D1DE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_981215B6D1DE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_930129505748","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_BEC694801E94","predicate":"cash_and_equivalents","value":"16,927,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 16,927,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_BEC694801E94, https://asof.is/claim/clm_BEC694801E94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_BEC694801E94","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6F4EA3581211","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_D532699D7671","predicate":"quarterly_research_and_development","value":"1,057,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,057,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_D532699D7671, https://asof.is/claim/clm_D532699D7671, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_D532699D7671","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56C675C78488","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_E4C5A9D23585","predicate":"quarterly_revenue","value":"5,281,000,000 United States dollar","valid_from":"2019-03-31","valid_to":"2019-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,281,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_E4C5A9D23585, https://asof.is/claim/clm_E4C5A9D23585, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_E4C5A9D23585","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_57A874E5A2DF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_64804BC6C18F","predicate":"shares_outstanding","value":"1,275,510,558 shares","valid_from":"2019-02-15","valid_to":"2019-04-30","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,275,510,558 shares\", as of 2019-02-15 (until 2019-04-30). Claim clm_64804BC6C18F, https://asof.is/claim/clm_64804BC6C18F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_64804BC6C18F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_55FF6D3BF284","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_01DEEAA7959E","predicate":"total_equity","value":"21,387,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-03-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,387,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_01DEEAA7959E, https://asof.is/claim/clm_01DEEAA7959E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_01DEEAA7959E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_427FE77026B1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_2C70360428CB","predicate":"revenue","value":"22,127,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 22,127,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_2C70360428CB, https://asof.is/claim/clm_2C70360428CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_2C70360428CB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_43120E77E428","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_4AC1B328D986","predicate":"operating_income","value":"8,200,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 8,200,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_4AC1B328D986, https://asof.is/claim/clm_4AC1B328D986, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_4AC1B328D986","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_023882052B6B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_84B3E38A3786","predicate":"cash_and_equivalents","value":"17,940,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-03-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 17,940,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_84B3E38A3786, https://asof.is/claim/clm_84B3E38A3786, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_84B3E38A3786","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BEC694801E94","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_A4D93ABC998F","predicate":"research_and_development","value":"5,018,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 5,018,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_A4D93ABC998F, https://asof.is/claim/clm_A4D93ABC998F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_A4D93ABC998F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF2F795524C5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_F6D84B82A4B7","predicate":"net_income","value":"5,455,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 5,455,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_F6D84B82A4B7, https://asof.is/claim/clm_F6D84B82A4B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_F6D84B82A4B7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E9B23117B9AF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_F8D980C66571","predicate":"total_assets","value":"63,675,000,000 United States dollar","valid_from":"2018-12-31","valid_to":"2019-03-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 63,675,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_F8D980C66571, https://asof.is/claim/clm_F8D980C66571, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_F8D980C66571","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7C0CBF1B6C32","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_9310E67C75CD","predicate":"shares_outstanding","value":"1,293,619,612 shares","valid_from":"2018-10-30","valid_to":"2019-02-15","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,293,619,612 shares\", as of 2018-10-30 (until 2019-02-15). Claim clm_9310E67C75CD, https://asof.is/claim/clm_9310E67C75CD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_9310E67C75CD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_64804BC6C18F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_1F83C4577253","predicate":"quarterly_revenue","value":"5,596,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,596,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_1F83C4577253, https://asof.is/claim/clm_1F83C4577253, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_1F83C4577253","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E4C5A9D23585","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_4163B40D60DC","predicate":"quarterly_net_income","value":"2,097,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,097,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_4163B40D60DC, https://asof.is/claim/clm_4163B40D60DC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_4163B40D60DC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_981215B6D1DE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_6208207FCA1C","predicate":"total_assets","value":"64,305,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 64,305,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_6208207FCA1C, https://asof.is/claim/clm_6208207FCA1C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_6208207FCA1C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F8D980C66571","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_914CFB3695E1","predicate":"quarterly_research_and_development","value":"939,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 939,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_914CFB3695E1, https://asof.is/claim/clm_914CFB3695E1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_914CFB3695E1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D532699D7671","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_C97C95BA7944","predicate":"cash_and_equivalents","value":"14,569,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 14,569,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_C97C95BA7944, https://asof.is/claim/clm_C97C95BA7944, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_C97C95BA7944","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_84B3E38A3786","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_EB6EC79E44BE","predicate":"total_equity","value":"22,861,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2018-12-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,861,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_EB6EC79E44BE, https://asof.is/claim/clm_EB6EC79E44BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_EB6EC79E44BE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_01DEEAA7959E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_F552A8FA3730","predicate":"quarterly_operating_income","value":"2,623,000,000 United States dollar","valid_from":"2018-09-30","valid_to":"2019-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,623,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_F552A8FA3730, https://asof.is/claim/clm_F552A8FA3730, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_F552A8FA3730","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_304B07F7B38F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_E80445428580","predicate":"shares_outstanding","value":"1,296,340,593 shares","valid_from":"2018-07-30","valid_to":"2018-10-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,296,340,593 shares\", as of 2018-07-30 (until 2018-10-30). Claim clm_E80445428580, https://asof.is/claim/clm_E80445428580, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_E80445428580","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9310E67C75CD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_30747CB3FFA8","predicate":"total_equity","value":"21,672,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 21,672,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_30747CB3FFA8, https://asof.is/claim/clm_30747CB3FFA8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_30747CB3FFA8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EB6EC79E44BE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_327B4DC1B791","predicate":"cash_and_equivalents","value":"13,234,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 13,234,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_327B4DC1B791, https://asof.is/claim/clm_327B4DC1B791, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_327B4DC1B791","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C97C95BA7944","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_45E4E089CC81","predicate":"total_assets","value":"65,355,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 65,355,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_45E4E089CC81, https://asof.is/claim/clm_45E4E089CC81, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_45E4E089CC81","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6208207FCA1C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_C34C93C7683D","predicate":"quarterly_operating_income","value":"2,280,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,280,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_C34C93C7683D, https://asof.is/claim/clm_C34C93C7683D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_C34C93C7683D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F552A8FA3730","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_E1F6AE4E3122","predicate":"quarterly_research_and_development","value":"1,192,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,192,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_E1F6AE4E3122, https://asof.is/claim/clm_E1F6AE4E3122, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_E1F6AE4E3122","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_914CFB3695E1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_F8567009A977","predicate":"quarterly_revenue","value":"5,648,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,648,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_F8567009A977, https://asof.is/claim/clm_F8567009A977, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_F8567009A977","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1F83C4577253","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_FD40C1416217","predicate":"quarterly_net_income","value":"1,817,000,000 United States dollar","valid_from":"2018-06-30","valid_to":"2018-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,817,000,000 United States dollar\", as of 2018-06-30 (until 2018-09-30). Claim clm_FD40C1416217, https://asof.is/claim/clm_FD40C1416217, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_FD40C1416217","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4163B40D60DC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_A4949CF68D82","predicate":"shares_outstanding","value":"1,300,260,832 shares","valid_from":"2018-04-30","valid_to":"2018-07-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,300,260,832 shares\", as of 2018-04-30 (until 2018-07-30). Claim clm_A4949CF68D82, https://asof.is/claim/clm_A4949CF68D82, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_A4949CF68D82","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E80445428580","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_3B5A1FA2D337","predicate":"cash_and_equivalents","value":"7,643,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 7,643,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_3B5A1FA2D337, https://asof.is/claim/clm_3B5A1FA2D337, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_3B5A1FA2D337","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_327B4DC1B791","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_60A396F25E49","predicate":"quarterly_revenue","value":"5,088,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2019-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 5,088,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_60A396F25E49, https://asof.is/claim/clm_60A396F25E49, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm.","url":"https://asof.is/claim/clm_60A396F25E49","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F8567009A977","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000014/0000882095-19-000014-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2019","published_at":"2019-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2019, filed 2019-05-08"}},{"id":"clm_AAB4DD2B4052","predicate":"quarterly_net_income","value":"1,538,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 1,538,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_AAB4DD2B4052, https://asof.is/claim/clm_AAB4DD2B4052, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_AAB4DD2B4052","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FD40C1416217","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_B7A025B4E972","predicate":"total_assets","value":"65,381,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 65,381,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_B7A025B4E972, https://asof.is/claim/clm_B7A025B4E972, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_B7A025B4E972","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_45E4E089CC81","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_BADB05CE1396","predicate":"quarterly_research_and_development","value":"937,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 937,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_BADB05CE1396, https://asof.is/claim/clm_BADB05CE1396, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_BADB05CE1396","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E1F6AE4E3122","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_E8767F1F6334","predicate":"quarterly_operating_income","value":"2,153,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 2,153,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_E8767F1F6334, https://asof.is/claim/clm_E8767F1F6334, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_E8767F1F6334","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C34C93C7683D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_FC73834F60CC","predicate":"total_equity","value":"20,591,000,000 United States dollar","valid_from":"2018-03-31","valid_to":"2018-06-30","published":"2018-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,591,000,000 United States dollar\", as of 2018-03-31 (until 2018-06-30). Claim clm_FC73834F60CC, https://asof.is/claim/clm_FC73834F60CC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm.","url":"https://asof.is/claim/clm_FC73834F60CC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_30747CB3FFA8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000015/0000882095-18-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2018","published_at":"2018-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-05-09"}},{"id":"clm_404C97BD98A7","predicate":"shares_outstanding","value":"1,309,967,781 shares","valid_from":"2018-02-15","valid_to":"2018-04-30","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,309,967,781 shares\", as of 2018-02-15 (until 2018-04-30). Claim clm_404C97BD98A7, https://asof.is/claim/clm_404C97BD98A7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_404C97BD98A7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A4949CF68D82","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_27E7D83B62B4","predicate":"revenue","value":"26,107,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 26,107,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_27E7D83B62B4, https://asof.is/claim/clm_27E7D83B62B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_27E7D83B62B4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C70360428CB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_58599489AE93","predicate":"total_equity","value":"20,442,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,442,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_58599489AE93, https://asof.is/claim/clm_58599489AE93, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_58599489AE93","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FC73834F60CC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_60315DE617E0","predicate":"cash_and_equivalents","value":"7,588,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 7,588,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_60315DE617E0, https://asof.is/claim/clm_60315DE617E0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_60315DE617E0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3B5A1FA2D337","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_757554EF6848","predicate":"operating_income","value":"14,124,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 14,124,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_757554EF6848, https://asof.is/claim/clm_757554EF6848, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_757554EF6848","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4AC1B328D986","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_CBC8CA566644","predicate":"total_assets","value":"70,283,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-03-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 70,283,000,000 United States dollar\", as of 2017-12-31 (until 2018-03-31). Claim clm_CBC8CA566644, https://asof.is/claim/clm_CBC8CA566644, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_CBC8CA566644","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B7A025B4E972","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_E7E834C64911","predicate":"net_income","value":"4,628,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 4,628,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_E7E834C64911, https://asof.is/claim/clm_E7E834C64911, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_E7E834C64911","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F6D84B82A4B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_F57660C96CD5","predicate":"research_and_development","value":"3,734,000,000 United States dollar","valid_from":"2017-12-31","valid_to":"2018-12-31","published":"2018-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 3,734,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_F57660C96CD5, https://asof.is/claim/clm_F57660C96CD5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm.","url":"https://asof.is/claim/clm_F57660C96CD5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A4D93ABC998F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/0000882095-18-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2017","published_at":"2018-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2017, filed 2018-02-27"}},{"id":"clm_CF2D067A89F6","predicate":"shares_outstanding","value":"1,306,268,996 shares","valid_from":"2017-10-31","valid_to":"2018-02-15","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,306,268,996 shares\", as of 2017-10-31 (until 2018-02-15). Claim clm_CF2D067A89F6, https://asof.is/claim/clm_CF2D067A89F6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_CF2D067A89F6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_404C97BD98A7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_5093D8587F37","predicate":"quarterly_revenue","value":"6,512,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2018-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,512,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_5093D8587F37, https://asof.is/claim/clm_5093D8587F37, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm.","url":"https://asof.is/claim/clm_5093D8587F37","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60A396F25E49","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000029/0000882095-18-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2018","published_at":"2018-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2018, filed 2018-11-06"}},{"id":"clm_6553928A4F4E","predicate":"cash_and_equivalents","value":"11,508,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 11,508,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_6553928A4F4E, https://asof.is/claim/clm_6553928A4F4E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_6553928A4F4E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60315DE617E0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_658A565141FB","predicate":"quarterly_operating_income","value":"3,812,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,812,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_658A565141FB, https://asof.is/claim/clm_658A565141FB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_658A565141FB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E8767F1F6334","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_74BBE0739D9C","predicate":"quarterly_net_income","value":"2,718,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,718,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_74BBE0739D9C, https://asof.is/claim/clm_74BBE0739D9C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_74BBE0739D9C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AAB4DD2B4052","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_7E2E193AAECA","predicate":"total_equity","value":"24,845,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 24,845,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_7E2E193AAECA, https://asof.is/claim/clm_7E2E193AAECA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_7E2E193AAECA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58599489AE93","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_94616F3E1AEA","predicate":"total_assets","value":"64,662,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2017-12-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 64,662,000,000 United States dollar\", as of 2017-09-30 (until 2017-12-31). Claim clm_94616F3E1AEA, https://asof.is/claim/clm_94616F3E1AEA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_94616F3E1AEA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CBC8CA566644","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_C314071CED94","predicate":"quarterly_research_and_development","value":"789,000,000 United States dollar","valid_from":"2017-09-30","valid_to":"2018-03-31","published":"2017-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 789,000,000 United States dollar\", as of 2017-09-30 (until 2018-03-31). Claim clm_C314071CED94, https://asof.is/claim/clm_C314071CED94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm.","url":"https://asof.is/claim/clm_C314071CED94","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BADB05CE1396","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000027/0000882095-17-000027-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2017","published_at":"2017-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2017, filed 2017-11-07"}},{"id":"clm_5F1621F78102","predicate":"shares_outstanding","value":"1,305,926,217 shares","valid_from":"2017-07-31","valid_to":"2017-10-31","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,305,926,217 shares\", as of 2017-07-31 (until 2017-10-31). Claim clm_5F1621F78102, https://asof.is/claim/clm_5F1621F78102, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_5F1621F78102","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CF2D067A89F6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_079E4DCAAED6","predicate":"quarterly_operating_income","value":"4,254,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 4,254,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_079E4DCAAED6, https://asof.is/claim/clm_079E4DCAAED6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_079E4DCAAED6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_658A565141FB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_3137B2FCB357","predicate":"quarterly_research_and_development","value":"864,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 864,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_3137B2FCB357, https://asof.is/claim/clm_3137B2FCB357, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_3137B2FCB357","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C314071CED94","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_359D7E1B8020","predicate":"quarterly_net_income","value":"3,073,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,073,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_359D7E1B8020, https://asof.is/claim/clm_359D7E1B8020, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_359D7E1B8020","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_74BBE0739D9C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_36D2C5AC16C0","predicate":"quarterly_revenue","value":"7,141,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2018-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,141,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_36D2C5AC16C0, https://asof.is/claim/clm_36D2C5AC16C0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm.","url":"https://asof.is/claim/clm_36D2C5AC16C0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5093D8587F37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000022/0000882095-18-000022-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2018","published_at":"2018-08-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2018, filed 2018-08-06"}},{"id":"clm_71AAC35B0398","predicate":"total_equity","value":"22,677,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 22,677,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_71AAC35B0398, https://asof.is/claim/clm_71AAC35B0398, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_71AAC35B0398","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7E2E193AAECA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_C0F22A4ECEE7","predicate":"total_assets","value":"60,263,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 60,263,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_C0F22A4ECEE7, https://asof.is/claim/clm_C0F22A4ECEE7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_C0F22A4ECEE7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_94616F3E1AEA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_FB17AC864D9C","predicate":"cash_and_equivalents","value":"8,712,000,000 United States dollar","valid_from":"2017-06-30","valid_to":"2017-09-30","published":"2017-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 8,712,000,000 United States dollar\", as of 2017-06-30 (until 2017-09-30). Claim clm_FB17AC864D9C, https://asof.is/claim/clm_FB17AC864D9C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm.","url":"https://asof.is/claim/clm_FB17AC864D9C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6553928A4F4E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000020/0000882095-17-000020-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2017","published_at":"2017-08-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-08-07"}},{"id":"clm_D1A23A561B3B","predicate":"shares_outstanding","value":"1,306,728,398 shares","valid_from":"2017-04-28","valid_to":"2017-07-31","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,306,728,398 shares\", as of 2017-04-28 (until 2017-07-31). Claim clm_D1A23A561B3B, https://asof.is/claim/clm_D1A23A561B3B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_D1A23A561B3B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5F1621F78102","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_08B75807F50B","predicate":"quarterly_net_income","value":"2,702,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,702,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_08B75807F50B, https://asof.is/claim/clm_08B75807F50B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_08B75807F50B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_359D7E1B8020","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_2C565010AFA4","predicate":"quarterly_revenue","value":"6,505,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,505,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_2C565010AFA4, https://asof.is/claim/clm_2C565010AFA4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_2C565010AFA4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_36D2C5AC16C0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_36523E1DC403","predicate":"quarterly_operating_income","value":"3,767,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,767,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_36523E1DC403, https://asof.is/claim/clm_36523E1DC403, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_36523E1DC403","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_079E4DCAAED6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_A199458E8799","predicate":"cash_and_equivalents","value":"10,285,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 10,285,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_A199458E8799, https://asof.is/claim/clm_A199458E8799, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_A199458E8799","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FB17AC864D9C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_AD7234D455A7","predicate":"quarterly_research_and_development","value":"931,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 931,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_AD7234D455A7, https://asof.is/claim/clm_AD7234D455A7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_AD7234D455A7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3137B2FCB357","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_B888594CFA0B","predicate":"total_equity","value":"20,441,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 20,441,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_B888594CFA0B, https://asof.is/claim/clm_B888594CFA0B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_B888594CFA0B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71AAC35B0398","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_DCE9F3C6B7BD","predicate":"total_assets","value":"57,701,000,000 United States dollar","valid_from":"2017-03-31","valid_to":"2017-06-30","published":"2017-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 57,701,000,000 United States dollar\", as of 2017-03-31 (until 2017-06-30). Claim clm_DCE9F3C6B7BD, https://asof.is/claim/clm_DCE9F3C6B7BD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm.","url":"https://asof.is/claim/clm_DCE9F3C6B7BD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C0F22A4ECEE7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000013/0000882095-17-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2017","published_at":"2017-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-10"}},{"id":"clm_D33C40190158","predicate":"shares_outstanding","value":"1,307,066,900 shares","valid_from":"2017-02-16","valid_to":"2017-04-28","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,307,066,900 shares\", as of 2017-02-16 (until 2017-04-28). Claim clm_D33C40190158, https://asof.is/claim/clm_D33C40190158, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_D33C40190158","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D1A23A561B3B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_69A3F1EE9840","predicate":"operating_income","value":"17,633,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 17,633,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_69A3F1EE9840, https://asof.is/claim/clm_69A3F1EE9840, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_69A3F1EE9840","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_757554EF6848","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_9015437E803C","predicate":"total_equity","value":"18,887,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,887,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_9015437E803C, https://asof.is/claim/clm_9015437E803C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_9015437E803C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B888594CFA0B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_976C69D91B06","predicate":"total_assets","value":"56,977,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 56,977,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_976C69D91B06, https://asof.is/claim/clm_976C69D91B06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_976C69D91B06","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DCE9F3C6B7BD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_990E09396E1F","predicate":"cash_and_equivalents","value":"8,229,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-03-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 8,229,000,000 United States dollar\", as of 2016-12-31 (until 2017-03-31). Claim clm_990E09396E1F, https://asof.is/claim/clm_990E09396E1F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_990E09396E1F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A199458E8799","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_A135DBE0E85A","predicate":"research_and_development","value":"5,098,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 5,098,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_A135DBE0E85A, https://asof.is/claim/clm_A135DBE0E85A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_A135DBE0E85A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F57660C96CD5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_ACDE59759096","predicate":"net_income","value":"13,501,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2017-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 13,501,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_ACDE59759096, https://asof.is/claim/clm_ACDE59759096, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm.","url":"https://asof.is/claim/clm_ACDE59759096","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E7E834C64911","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209517000006/0000882095-17-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2016","published_at":"2017-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-27"}},{"id":"clm_FC87519132B6","predicate":"revenue","value":"30,390,000,000 United States dollar","valid_from":"2016-12-31","valid_to":"2017-12-31","published":"2019-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 30,390,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_FC87519132B6, https://asof.is/claim/clm_FC87519132B6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm.","url":"https://asof.is/claim/clm_FC87519132B6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_27E7D83B62B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2018","published_at":"2019-02-26T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2018, filed 2019-02-26"}},{"id":"clm_4226A2D9D3FB","predicate":"shares_outstanding","value":"1,317,456,071 shares","valid_from":"2016-10-31","valid_to":"2017-02-16","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,317,456,071 shares\", as of 2016-10-31 (until 2017-02-16). Claim clm_4226A2D9D3FB, https://asof.is/claim/clm_4226A2D9D3FB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_4226A2D9D3FB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D33C40190158","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_4343230CB05B","predicate":"total_equity","value":"16,868,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 16,868,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_4343230CB05B, https://asof.is/claim/clm_4343230CB05B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_4343230CB05B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9015437E803C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_6416AB6D896A","predicate":"quarterly_operating_income","value":"4,399,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 4,399,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_6416AB6D896A, https://asof.is/claim/clm_6416AB6D896A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_6416AB6D896A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_36523E1DC403","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_6462A95E705D","predicate":"quarterly_net_income","value":"3,330,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,330,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_6462A95E705D, https://asof.is/claim/clm_6462A95E705D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_6462A95E705D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08B75807F50B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_7055B95F726C","predicate":"quarterly_research_and_development","value":"1,141,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,141,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_7055B95F726C, https://asof.is/claim/clm_7055B95F726C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_7055B95F726C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_AD7234D455A7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_E2545AE7F426","predicate":"quarterly_revenue","value":"7,500,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2017-03-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,500,000,000 United States dollar\", as of 2016-09-30 (until 2017-03-31). Claim clm_E2545AE7F426, https://asof.is/claim/clm_E2545AE7F426, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_E2545AE7F426","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C565010AFA4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_E971A4A44267","predicate":"cash_and_equivalents","value":"9,809,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 9,809,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_E971A4A44267, https://asof.is/claim/clm_E971A4A44267, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_E971A4A44267","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_990E09396E1F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_EE2C45744700","predicate":"total_assets","value":"56,609,000,000 United States dollar","valid_from":"2016-09-30","valid_to":"2016-12-31","published":"2016-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 56,609,000,000 United States dollar\", as of 2016-09-30 (until 2016-12-31). Claim clm_EE2C45744700, https://asof.is/claim/clm_EE2C45744700, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm.","url":"https://asof.is/claim/clm_EE2C45744700","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_976C69D91B06","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000060/0000882095-16-000060-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2016","published_at":"2016-11-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-11-07"}},{"id":"clm_0540BDF9635D","predicate":"shares_outstanding","value":"1,319,658,489 shares","valid_from":"2016-07-31","valid_to":"2016-10-31","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,319,658,489 shares\", as of 2016-07-31 (until 2016-10-31). Claim clm_0540BDF9635D, https://asof.is/claim/clm_0540BDF9635D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_0540BDF9635D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4226A2D9D3FB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_08545099492F","predicate":"cash_and_equivalents","value":"6,485,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 6,485,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_08545099492F, https://asof.is/claim/clm_08545099492F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_08545099492F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E971A4A44267","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_12950DB90363","predicate":"quarterly_net_income","value":"3,497,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,497,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_12950DB90363, https://asof.is/claim/clm_12950DB90363, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_12950DB90363","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6462A95E705D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_2114180CCC8B","predicate":"quarterly_research_and_development","value":"1,484,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,484,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_2114180CCC8B, https://asof.is/claim/clm_2114180CCC8B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_2114180CCC8B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7055B95F726C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_26F557F5D548","predicate":"quarterly_operating_income","value":"4,538,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 4,538,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_26F557F5D548, https://asof.is/claim/clm_26F557F5D548, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_26F557F5D548","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6416AB6D896A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_A37712B935A5","predicate":"total_equity","value":"15,536,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 15,536,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_A37712B935A5, https://asof.is/claim/clm_A37712B935A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_A37712B935A5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4343230CB05B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_CC9217F333A8","predicate":"quarterly_revenue","value":"7,776,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,776,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_CC9217F333A8, https://asof.is/claim/clm_CC9217F333A8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_CC9217F333A8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E2545AE7F426","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_EC34211A91A5","predicate":"total_assets","value":"49,980,000,000 United States dollar","valid_from":"2016-06-30","valid_to":"2016-09-30","published":"2016-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 49,980,000,000 United States dollar\", as of 2016-06-30 (until 2016-09-30). Claim clm_EC34211A91A5, https://asof.is/claim/clm_EC34211A91A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm.","url":"https://asof.is/claim/clm_EC34211A91A5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EE2C45744700","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000054/0000882095-16-000054-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2016","published_at":"2016-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-05"}},{"id":"clm_CE80F4959ACE","predicate":"shares_outstanding","value":"1,331,821,506 shares","valid_from":"2016-04-29","valid_to":"2016-07-31","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,331,821,506 shares\", as of 2016-04-29 (until 2016-07-31). Claim clm_CE80F4959ACE, https://asof.is/claim/clm_CE80F4959ACE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_CE80F4959ACE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0540BDF9635D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_2CF37CEBBBB9","predicate":"cash_and_equivalents","value":"6,315,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 6,315,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_2CF37CEBBBB9, https://asof.is/claim/clm_2CF37CEBBBB9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_2CF37CEBBBB9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_08545099492F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_3C1AA086404C","predicate":"quarterly_operating_income","value":"4,651,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 4,651,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_3C1AA086404C, https://asof.is/claim/clm_3C1AA086404C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_3C1AA086404C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_26F557F5D548","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_4A46A41D0E94","predicate":"quarterly_research_and_development","value":"1,265,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,265,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_4A46A41D0E94, https://asof.is/claim/clm_4A46A41D0E94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_4A46A41D0E94","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2114180CCC8B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_5C721A2A8DF5","predicate":"total_equity","value":"13,398,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,398,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_5C721A2A8DF5, https://asof.is/claim/clm_5C721A2A8DF5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_5C721A2A8DF5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A37712B935A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_78CFE1D6629B","predicate":"quarterly_revenue","value":"7,794,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,794,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_78CFE1D6629B, https://asof.is/claim/clm_78CFE1D6629B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_78CFE1D6629B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CC9217F333A8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_85B2D6656C9A","predicate":"quarterly_net_income","value":"3,566,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,566,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_85B2D6656C9A, https://asof.is/claim/clm_85B2D6656C9A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_85B2D6656C9A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_12950DB90363","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_DA37C019E024","predicate":"total_assets","value":"47,765,000,000 United States dollar","valid_from":"2016-03-31","valid_to":"2016-06-30","published":"2016-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 47,765,000,000 United States dollar\", as of 2016-03-31 (until 2016-06-30). Claim clm_DA37C019E024, https://asof.is/claim/clm_DA37C019E024, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm.","url":"https://asof.is/claim/clm_DA37C019E024","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EC34211A91A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000046/0000882095-16-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2016","published_at":"2016-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-06"}},{"id":"clm_7B29D67F521F","predicate":"shares_outstanding","value":"1,366,845,691 shares","valid_from":"2016-02-12","valid_to":"2016-04-29","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,366,845,691 shares\", as of 2016-02-12 (until 2016-04-29). Claim clm_7B29D67F521F, https://asof.is/claim/clm_7B29D67F521F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_7B29D67F521F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CE80F4959ACE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_27F3DD63E611","predicate":"total_equity","value":"18,534,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 18,534,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_27F3DD63E611, https://asof.is/claim/clm_27F3DD63E611, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_27F3DD63E611","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5C721A2A8DF5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_3CA462AADF8A","predicate":"operating_income","value":"22,193,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 22,193,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_3CA462AADF8A, https://asof.is/claim/clm_3CA462AADF8A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_3CA462AADF8A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_69A3F1EE9840","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_963EB0743197","predicate":"revenue","value":"32,639,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 32,639,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_963EB0743197, https://asof.is/claim/clm_963EB0743197, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_963EB0743197","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FC87519132B6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_C611C725BFCF","predicate":"research_and_development","value":"3,014,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 3,014,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_C611C725BFCF, https://asof.is/claim/clm_C611C725BFCF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_C611C725BFCF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A135DBE0E85A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_D56AF049FD72","predicate":"total_assets","value":"51,839,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 51,839,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_D56AF049FD72, https://asof.is/claim/clm_D56AF049FD72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_D56AF049FD72","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DA37C019E024","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_E1EF723628E4","predicate":"net_income","value":"18,108,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-12-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 18,108,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_E1EF723628E4, https://asof.is/claim/clm_E1EF723628E4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_E1EF723628E4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ACDE59759096","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_F514161AC740","predicate":"cash_and_equivalents","value":"12,851,000,000 United States dollar","valid_from":"2015-12-31","valid_to":"2016-03-31","published":"2016-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 12,851,000,000 United States dollar\", as of 2015-12-31 (until 2016-03-31). Claim clm_F514161AC740, https://asof.is/claim/clm_F514161AC740, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm.","url":"https://asof.is/claim/clm_F514161AC740","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2CF37CEBBBB9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2015","published_at":"2016-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-24"}},{"id":"clm_5B012B612E72","predicate":"shares_outstanding","value":"1,441,180,186 shares","valid_from":"2015-10-30","valid_to":"2016-02-12","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,441,180,186 shares\", as of 2015-10-30 (until 2016-02-12). Claim clm_5B012B612E72, https://asof.is/claim/clm_5B012B612E72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_5B012B612E72","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7B29D67F521F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_1FCA56C9FDDA","predicate":"quarterly_revenue","value":"8,295,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 8,295,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_1FCA56C9FDDA, https://asof.is/claim/clm_1FCA56C9FDDA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_1FCA56C9FDDA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78CFE1D6629B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_53DDA1B5667A","predicate":"total_assets","value":"50,637,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 50,637,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_53DDA1B5667A, https://asof.is/claim/clm_53DDA1B5667A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_53DDA1B5667A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D56AF049FD72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_5C3945CA6EA3","predicate":"quarterly_operating_income","value":"5,585,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 5,585,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_5C3945CA6EA3, https://asof.is/claim/clm_5C3945CA6EA3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_5C3945CA6EA3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3C1AA086404C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_71BC7C11F77A","predicate":"total_equity","value":"17,414,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 17,414,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_71BC7C11F77A, https://asof.is/claim/clm_71BC7C11F77A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_71BC7C11F77A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_27F3DD63E611","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_86055E0F3919","predicate":"quarterly_research_and_development","value":"743,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 743,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_86055E0F3919, https://asof.is/claim/clm_86055E0F3919, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_86055E0F3919","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4A46A41D0E94","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_B60BC536C441","predicate":"quarterly_net_income","value":"4,600,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2016-03-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 4,600,000,000 United States dollar\", as of 2015-09-30 (until 2016-03-31). Claim clm_B60BC536C441, https://asof.is/claim/clm_B60BC536C441, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_B60BC536C441","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_85B2D6656C9A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_E121FF6F1BD4","predicate":"cash_and_equivalents","value":"13,965,000,000 United States dollar","valid_from":"2015-09-30","valid_to":"2015-12-31","published":"2015-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 13,965,000,000 United States dollar\", as of 2015-09-30 (until 2015-12-31). Claim clm_E121FF6F1BD4, https://asof.is/claim/clm_E121FF6F1BD4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm.","url":"https://asof.is/claim/clm_E121FF6F1BD4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F514161AC740","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000033/0000882095-15-000033-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2015","published_at":"2015-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-04"}},{"id":"clm_276D7713D95E","predicate":"shares_outstanding","value":"1,467,605,502 shares","valid_from":"2015-07-31","valid_to":"2015-10-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,467,605,502 shares\", as of 2015-07-31 (until 2015-10-30). Claim clm_276D7713D95E, https://asof.is/claim/clm_276D7713D95E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_276D7713D95E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5B012B612E72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_3B528F1C96CB","predicate":"quarterly_operating_income","value":"5,616,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 5,616,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_3B528F1C96CB, https://asof.is/claim/clm_3B528F1C96CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_3B528F1C96CB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5C3945CA6EA3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_60E4DC378174","predicate":"cash_and_equivalents","value":"7,417,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 7,417,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_60E4DC378174, https://asof.is/claim/clm_60E4DC378174, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_60E4DC378174","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E121FF6F1BD4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_B77960C40400","predicate":"quarterly_revenue","value":"8,244,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 8,244,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_B77960C40400, https://asof.is/claim/clm_B77960C40400, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_B77960C40400","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1FCA56C9FDDA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_BD4CAF70327B","predicate":"quarterly_research_and_development","value":"818,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 818,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_BD4CAF70327B, https://asof.is/claim/clm_BD4CAF70327B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_BD4CAF70327B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_86055E0F3919","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_C59C0F08C1D6","predicate":"total_assets","value":"39,167,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 39,167,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_C59C0F08C1D6, https://asof.is/claim/clm_C59C0F08C1D6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_C59C0F08C1D6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_53DDA1B5667A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_DF79C5D89594","predicate":"quarterly_net_income","value":"4,492,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 4,492,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_DF79C5D89594, https://asof.is/claim/clm_DF79C5D89594, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_DF79C5D89594","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B60BC536C441","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_EA7023B67827","predicate":"total_equity","value":"16,287,000,000 United States dollar","valid_from":"2015-06-30","valid_to":"2015-09-30","published":"2015-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 16,287,000,000 United States dollar\", as of 2015-06-30 (until 2015-09-30). Claim clm_EA7023B67827, https://asof.is/claim/clm_EA7023B67827, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm.","url":"https://asof.is/claim/clm_EA7023B67827","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71BC7C11F77A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000026/0000882095-15-000026-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2015","published_at":"2015-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-05"}},{"id":"clm_D5531C297C82","predicate":"shares_outstanding","value":"1,469,605,980 shares","valid_from":"2015-04-30","valid_to":"2015-07-31","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,469,605,980 shares\", as of 2015-04-30 (until 2015-07-31). Claim clm_D5531C297C82, https://asof.is/claim/clm_D5531C297C82, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_D5531C297C82","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_276D7713D95E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_140D00598977","predicate":"total_assets","value":"38,321,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 38,321,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_140D00598977, https://asof.is/claim/clm_140D00598977, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_140D00598977","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C59C0F08C1D6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_4B94008EAEAA","predicate":"quarterly_revenue","value":"7,594,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 7,594,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_4B94008EAEAA, https://asof.is/claim/clm_4B94008EAEAA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_4B94008EAEAA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B77960C40400","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_6AAA25871D37","predicate":"cash_and_equivalents","value":"10,635,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 10,635,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_6AAA25871D37, https://asof.is/claim/clm_6AAA25871D37, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_6AAA25871D37","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60E4DC378174","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_71908216DDFE","predicate":"total_equity","value":"17,180,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 17,180,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_71908216DDFE, https://asof.is/claim/clm_71908216DDFE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_71908216DDFE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EA7023B67827","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_8B847A3897B8","predicate":"quarterly_operating_income","value":"5,371,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 5,371,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_8B847A3897B8, https://asof.is/claim/clm_8B847A3897B8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_8B847A3897B8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3B528F1C96CB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_BC16F61ED0DA","predicate":"quarterly_net_income","value":"4,333,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 4,333,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_BC16F61ED0DA, https://asof.is/claim/clm_BC16F61ED0DA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_BC16F61ED0DA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DF79C5D89594","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_C007A487B9D0","predicate":"quarterly_research_and_development","value":"696,000,000 United States dollar","valid_from":"2015-03-31","valid_to":"2015-06-30","published":"2015-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 696,000,000 United States dollar\", as of 2015-03-31 (until 2015-06-30). Claim clm_C007A487B9D0, https://asof.is/claim/clm_C007A487B9D0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm.","url":"https://asof.is/claim/clm_C007A487B9D0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BD4CAF70327B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000017/0000882095-15-000017-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2015","published_at":"2015-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2015, filed 2015-05-08"}},{"id":"clm_46E3C4C88388","predicate":"shares_outstanding","value":"1,489,401,683 shares","valid_from":"2015-02-13","valid_to":"2015-04-30","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,489,401,683 shares\", as of 2015-02-13 (until 2015-04-30). Claim clm_46E3C4C88388, https://asof.is/claim/clm_46E3C4C88388, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_46E3C4C88388","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D5531C297C82","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_617CC39EB4D4","predicate":"revenue","value":"24,890,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 24,890,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_617CC39EB4D4, https://asof.is/claim/clm_617CC39EB4D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_617CC39EB4D4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_963EB0743197","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_7B67F0C2B7A3","predicate":"cash_and_equivalents","value":"10,027,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 10,027,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_7B67F0C2B7A3, https://asof.is/claim/clm_7B67F0C2B7A3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_7B67F0C2B7A3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6AAA25871D37","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_830AD3CBC862","predicate":"operating_income","value":"15,265,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 15,265,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_830AD3CBC862, https://asof.is/claim/clm_830AD3CBC862, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_830AD3CBC862","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3CA462AADF8A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_8CF7142E8E33","predicate":"total_equity","value":"15,426,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 15,426,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_8CF7142E8E33, https://asof.is/claim/clm_8CF7142E8E33, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_8CF7142E8E33","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71908216DDFE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_918922602D80","predicate":"net_income","value":"12,101,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 12,101,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_918922602D80, https://asof.is/claim/clm_918922602D80, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_918922602D80","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E1EF723628E4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_D01DF9FC4DE7","predicate":"research_and_development","value":"2,854,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-12-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 2,854,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_D01DF9FC4DE7, https://asof.is/claim/clm_D01DF9FC4DE7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_D01DF9FC4DE7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C611C725BFCF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_FEBA53BD0180","predicate":"total_assets","value":"34,664,000,000 United States dollar","valid_from":"2014-12-31","valid_to":"2015-03-31","published":"2015-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 34,664,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-31). Claim clm_FEBA53BD0180, https://asof.is/claim/clm_FEBA53BD0180, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm.","url":"https://asof.is/claim/clm_FEBA53BD0180","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_140D00598977","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2014","published_at":"2015-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-25"}},{"id":"clm_F1B081019EDB","predicate":"shares_outstanding","value":"1,508,664,333 shares","valid_from":"2014-10-31","valid_to":"2015-02-13","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,508,664,333 shares\", as of 2014-10-31 (until 2015-02-13). Claim clm_F1B081019EDB, https://asof.is/claim/clm_F1B081019EDB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_F1B081019EDB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_46E3C4C88388","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_0BA87D52CC96","predicate":"quarterly_research_and_development","value":"630,466,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 630,466,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_0BA87D52CC96, https://asof.is/claim/clm_0BA87D52CC96, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_0BA87D52CC96","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C007A487B9D0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_197FF9089D7D","predicate":"cash_and_equivalents","value":"6,209,060,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 6,209,060,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_197FF9089D7D, https://asof.is/claim/clm_197FF9089D7D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_197FF9089D7D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7B67F0C2B7A3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_2DA8137DB2EA","predicate":"quarterly_net_income","value":"2,731,274,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,731,274,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_2DA8137DB2EA, https://asof.is/claim/clm_2DA8137DB2EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_2DA8137DB2EA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BC16F61ED0DA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_77E644719A6A","predicate":"total_equity","value":"13,566,223,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,566,223,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_77E644719A6A, https://asof.is/claim/clm_77E644719A6A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_77E644719A6A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8CF7142E8E33","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_796B0D2AB76A","predicate":"quarterly_operating_income","value":"3,479,223,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,479,223,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_796B0D2AB76A, https://asof.is/claim/clm_796B0D2AB76A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_796B0D2AB76A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8B847A3897B8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_7F1BCBD81907","predicate":"total_assets","value":"28,844,393,000 United States dollar","valid_from":"2014-09-30","valid_to":"2014-12-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 28,844,393,000 United States dollar\", as of 2014-09-30 (until 2014-12-31). Claim clm_7F1BCBD81907, https://asof.is/claim/clm_7F1BCBD81907, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_7F1BCBD81907","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FEBA53BD0180","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_DF1ED50540CF","predicate":"quarterly_revenue","value":"6,041,832,000 United States dollar","valid_from":"2014-09-30","valid_to":"2015-03-31","published":"2014-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,041,832,000 United States dollar\", as of 2014-09-30 (until 2015-03-31). Claim clm_DF1ED50540CF, https://asof.is/claim/clm_DF1ED50540CF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm.","url":"https://asof.is/claim/clm_DF1ED50540CF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4B94008EAEAA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000051/0000882095-14-000051-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2014","published_at":"2014-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2014, filed 2014-11-05"}},{"id":"clm_1541FF3D3905","predicate":"shares_outstanding","value":"1,511,670,456 shares","valid_from":"2014-07-25","valid_to":"2014-10-31","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,511,670,456 shares\", as of 2014-07-25 (until 2014-10-31). Claim clm_1541FF3D3905, https://asof.is/claim/clm_1541FF3D3905, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_1541FF3D3905","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F1B081019EDB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_073B8D19A679","predicate":"total_assets","value":"31,206,164,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 31,206,164,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_073B8D19A679, https://asof.is/claim/clm_073B8D19A679, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_073B8D19A679","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7F1BCBD81907","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_401F7ECEA86E","predicate":"cash_and_equivalents","value":"8,730,522,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 8,730,522,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_401F7ECEA86E, https://asof.is/claim/clm_401F7ECEA86E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_401F7ECEA86E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_197FF9089D7D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_42E6B9EB2E6E","predicate":"quarterly_operating_income","value":"4,412,755,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 4,412,755,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_42E6B9EB2E6E, https://asof.is/claim/clm_42E6B9EB2E6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_42E6B9EB2E6E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_796B0D2AB76A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_75A0E5882CB0","predicate":"total_equity","value":"16,090,629,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 16,090,629,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_75A0E5882CB0, https://asof.is/claim/clm_75A0E5882CB0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_75A0E5882CB0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_77E644719A6A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_90DDD6E3BE13","predicate":"quarterly_net_income","value":"3,655,593,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 3,655,593,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_90DDD6E3BE13, https://asof.is/claim/clm_90DDD6E3BE13, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_90DDD6E3BE13","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2DA8137DB2EA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_9B9748234060","predicate":"quarterly_revenue","value":"6,534,943,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 6,534,943,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_9B9748234060, https://asof.is/claim/clm_9B9748234060, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_9B9748234060","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DF1ED50540CF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_B0CF038E671F","predicate":"quarterly_research_and_development","value":"583,924,000 United States dollar","valid_from":"2014-06-30","valid_to":"2014-09-30","published":"2014-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 583,924,000 United States dollar\", as of 2014-06-30 (until 2014-09-30). Claim clm_B0CF038E671F, https://asof.is/claim/clm_B0CF038E671F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm.","url":"https://asof.is/claim/clm_B0CF038E671F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0BA87D52CC96","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000038/0000882095-14-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2014","published_at":"2014-08-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2014, filed 2014-08-04"}},{"id":"clm_7AB4B128BE59","predicate":"shares_outstanding","value":"1,535,682,107 shares","valid_from":"2014-04-25","valid_to":"2014-07-25","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,535,682,107 shares\", as of 2014-04-25 (until 2014-07-25). Claim clm_7AB4B128BE59, https://asof.is/claim/clm_7AB4B128BE59, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_7AB4B128BE59","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1541FF3D3905","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_184386B278EF","predicate":"quarterly_operating_income","value":"3,042,650,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,042,650,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_184386B278EF, https://asof.is/claim/clm_184386B278EF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_184386B278EF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_42E6B9EB2E6E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_7E2A196ABDE1","predicate":"quarterly_research_and_development","value":"594,978,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 594,978,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_7E2A196ABDE1, https://asof.is/claim/clm_7E2A196ABDE1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_7E2A196ABDE1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B0CF038E671F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_8216174716E2","predicate":"total_assets","value":"28,077,692,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 28,077,692,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_8216174716E2, https://asof.is/claim/clm_8216174716E2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_8216174716E2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_073B8D19A679","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_890094891137","predicate":"quarterly_revenue","value":"4,998,956,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 4,998,956,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_890094891137, https://asof.is/claim/clm_890094891137, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_890094891137","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9B9748234060","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_9855991F2297","predicate":"cash_and_equivalents","value":"6,404,153,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 6,404,153,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_9855991F2297, https://asof.is/claim/clm_9855991F2297, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_9855991F2297","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_401F7ECEA86E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_B07CC2780AF7","predicate":"total_equity","value":"13,387,322,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,387,322,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_B07CC2780AF7, https://asof.is/claim/clm_B07CC2780AF7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_B07CC2780AF7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_75A0E5882CB0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_BA19192F9268","predicate":"quarterly_net_income","value":"2,227,410,000 United States dollar","valid_from":"2014-03-31","valid_to":"2014-06-30","published":"2014-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,227,410,000 United States dollar\", as of 2014-03-31 (until 2014-06-30). Claim clm_BA19192F9268, https://asof.is/claim/clm_BA19192F9268, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm.","url":"https://asof.is/claim/clm_BA19192F9268","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_90DDD6E3BE13","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000024/0000882095-14-000024-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2014","published_at":"2014-05-07T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-07"}},{"id":"clm_76CC3B65DDF7","predicate":"shares_outstanding","value":"1,538,252,914 shares","valid_from":"2014-02-14","valid_to":"2014-04-25","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,538,252,914 shares\", as of 2014-02-14 (until 2014-04-25). Claim clm_76CC3B65DDF7, https://asof.is/claim/clm_76CC3B65DDF7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_76CC3B65DDF7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7AB4B128BE59","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_220CB7E7E545","predicate":"total_equity","value":"11,369,067,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 11,369,067,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_220CB7E7E545, https://asof.is/claim/clm_220CB7E7E545, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_220CB7E7E545","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B07CC2780AF7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_6099A9C5C90E","predicate":"cash_and_equivalents","value":"2,112,806,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 2,112,806,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_6099A9C5C90E, https://asof.is/claim/clm_6099A9C5C90E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_6099A9C5C90E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9855991F2297","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_97D551EB0FC8","predicate":"net_income","value":"3,074,808,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 3,074,808,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_97D551EB0FC8, https://asof.is/claim/clm_97D551EB0FC8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_97D551EB0FC8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_918922602D80","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_A89347762D25","predicate":"research_and_development","value":"2,119,756,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 2,119,756,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_A89347762D25, https://asof.is/claim/clm_A89347762D25, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_A89347762D25","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D01DF9FC4DE7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_BC08A5BEA713","predicate":"operating_income","value":"4,523,999,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 4,523,999,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_BC08A5BEA713, https://asof.is/claim/clm_BC08A5BEA713, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_BC08A5BEA713","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_830AD3CBC862","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_C43DA4F79044","predicate":"revenue","value":"11,201,688,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 11,201,688,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_C43DA4F79044, https://asof.is/claim/clm_C43DA4F79044, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_C43DA4F79044","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_617CC39EB4D4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_E924B4484B29","predicate":"total_assets","value":"22,496,785,000 United States dollar","valid_from":"2013-12-31","valid_to":"2014-03-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 22,496,785,000 United States dollar\", as of 2013-12-31 (until 2014-03-31). Claim clm_E924B4484B29, https://asof.is/claim/clm_E924B4484B29, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_E924B4484B29","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8216174716E2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_9A79DA553882","predicate":"shares_outstanding","value":"1,533,349,106 shares","valid_from":"2013-10-18","valid_to":"2014-02-14","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,533,349,106 shares\", as of 2013-10-18 (until 2014-02-14). Claim clm_9A79DA553882, https://asof.is/claim/clm_9A79DA553882, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_9A79DA553882","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76CC3B65DDF7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_04B6E015FE4D","predicate":"quarterly_operating_income","value":"1,147,861,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,147,861,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_04B6E015FE4D, https://asof.is/claim/clm_04B6E015FE4D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_04B6E015FE4D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_184386B278EF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_1038E6E3E9FF","predicate":"quarterly_net_income","value":"788,606,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 788,606,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_1038E6E3E9FF, https://asof.is/claim/clm_1038E6E3E9FF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_1038E6E3E9FF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA19192F9268","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_A5E3AA28CA83","predicate":"total_equity","value":"10,883,610,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 10,883,610,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_A5E3AA28CA83, https://asof.is/claim/clm_A5E3AA28CA83, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_A5E3AA28CA83","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_220CB7E7E545","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_C2B10DAAD114","predicate":"total_assets","value":"22,468,428,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 22,468,428,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_C2B10DAAD114, https://asof.is/claim/clm_C2B10DAAD114, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_C2B10DAAD114","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E924B4484B29","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_C46B94F27B3E","predicate":"quarterly_research_and_development","value":"546,244,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 546,244,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_C46B94F27B3E, https://asof.is/claim/clm_C46B94F27B3E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_C46B94F27B3E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7E2A196ABDE1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_ED3CDE5E3ED7","predicate":"quarterly_revenue","value":"2,782,833,000 United States dollar","valid_from":"2013-09-30","valid_to":"2014-03-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,782,833,000 United States dollar\", as of 2013-09-30 (until 2014-03-31). Claim clm_ED3CDE5E3ED7, https://asof.is/claim/clm_ED3CDE5E3ED7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_ED3CDE5E3ED7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_890094891137","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_F25C46B4CD20","predicate":"cash_and_equivalents","value":"2,010,736,000 United States dollar","valid_from":"2013-09-30","valid_to":"2013-12-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 2,010,736,000 United States dollar\", as of 2013-09-30 (until 2013-12-31). Claim clm_F25C46B4CD20, https://asof.is/claim/clm_F25C46B4CD20, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_F25C46B4CD20","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6099A9C5C90E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_725CDC55F839","predicate":"shares_outstanding","value":"1,530,626,021 shares","valid_from":"2013-07-19","valid_to":"2013-10-18","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,530,626,021 shares\", as of 2013-07-19 (until 2013-10-18). Claim clm_725CDC55F839, https://asof.is/claim/clm_725CDC55F839, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_725CDC55F839","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9A79DA553882","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_2C5E443BE540","predicate":"cash_and_equivalents","value":"2,202,176,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 2,202,176,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_2C5E443BE540, https://asof.is/claim/clm_2C5E443BE540, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_2C5E443BE540","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F25C46B4CD20","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_48AE970C35D8","predicate":"total_equity","value":"11,092,000,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 11,092,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_48AE970C35D8, https://asof.is/claim/clm_48AE970C35D8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_48AE970C35D8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A5E3AA28CA83","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_4A06B5FD1CCE","predicate":"total_assets","value":"22,624,374,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 22,624,374,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_4A06B5FD1CCE, https://asof.is/claim/clm_4A06B5FD1CCE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_4A06B5FD1CCE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C2B10DAAD114","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_89E5E1F0C38A","predicate":"quarterly_net_income","value":"772,605,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 772,605,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_89E5E1F0C38A, https://asof.is/claim/clm_89E5E1F0C38A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_89E5E1F0C38A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1038E6E3E9FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_BEDA44B8703A","predicate":"quarterly_research_and_development","value":"523,902,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 523,902,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_BEDA44B8703A, https://asof.is/claim/clm_BEDA44B8703A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_BEDA44B8703A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C46B94F27B3E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_D79BF1F1049A","predicate":"quarterly_revenue","value":"2,767,394,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,767,394,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_D79BF1F1049A, https://asof.is/claim/clm_D79BF1F1049A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_D79BF1F1049A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_ED3CDE5E3ED7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_E29B9FC01B82","predicate":"quarterly_operating_income","value":"1,153,838,000 United States dollar","valid_from":"2013-06-30","valid_to":"2013-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,153,838,000 United States dollar\", as of 2013-06-30 (until 2013-09-30). Claim clm_E29B9FC01B82, https://asof.is/claim/clm_E29B9FC01B82, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_E29B9FC01B82","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_04B6E015FE4D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_1D55B20D73A5","predicate":"shares_outstanding","value":"1,525,355,825 shares","valid_from":"2013-04-26","valid_to":"2013-07-19","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,525,355,825 shares\", as of 2013-04-26 (until 2013-07-19). Claim clm_1D55B20D73A5, https://asof.is/claim/clm_1D55B20D73A5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_1D55B20D73A5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_725CDC55F839","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_388E2FFF1D4B","predicate":"quarterly_net_income","value":"722,186,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 722,186,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_388E2FFF1D4B, https://asof.is/claim/clm_388E2FFF1D4B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_388E2FFF1D4B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_89E5E1F0C38A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_3F890EF44E32","predicate":"cash_and_equivalents","value":"1,863,972,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,863,972,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_3F890EF44E32, https://asof.is/claim/clm_3F890EF44E32, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_3F890EF44E32","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C5E443BE540","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_4716BEA47C18","predicate":"quarterly_research_and_development","value":"497,632,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 497,632,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_4716BEA47C18, https://asof.is/claim/clm_4716BEA47C18, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_4716BEA47C18","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BEDA44B8703A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_4AB2B075DD45","predicate":"quarterly_operating_income","value":"1,025,259,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,025,259,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_4AB2B075DD45, https://asof.is/claim/clm_4AB2B075DD45, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_4AB2B075DD45","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E29B9FC01B82","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_58A0E5DA42E6","predicate":"total_assets","value":"22,211,668,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 22,211,668,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_58A0E5DA42E6, https://asof.is/claim/clm_58A0E5DA42E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_58A0E5DA42E6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4A06B5FD1CCE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_85F66B9E6C53","predicate":"total_equity","value":"10,152,231,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 10,152,231,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_85F66B9E6C53, https://asof.is/claim/clm_85F66B9E6C53, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_85F66B9E6C53","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_48AE970C35D8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_CF7263DF8433","predicate":"quarterly_revenue","value":"2,531,635,000 United States dollar","valid_from":"2013-03-31","valid_to":"2013-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,531,635,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_CF7263DF8433, https://asof.is/claim/clm_CF7263DF8433, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_CF7263DF8433","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D79BF1F1049A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_45B915515FE5","predicate":"shares_outstanding","value":"1,522,392,518 shares","valid_from":"2013-02-15","valid_to":"2013-04-26","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,522,392,518 shares\", as of 2013-02-15 (until 2013-04-26). Claim clm_45B915515FE5, https://asof.is/claim/clm_45B915515FE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_45B915515FE5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1D55B20D73A5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_15468AB110B1","predicate":"total_assets","value":"21,239,838,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 21,239,838,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_15468AB110B1, https://asof.is/claim/clm_15468AB110B1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_15468AB110B1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_58A0E5DA42E6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_6D4418F572A9","predicate":"revenue","value":"9,702,517,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 9,702,517,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_6D4418F572A9, https://asof.is/claim/clm_6D4418F572A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_6D4418F572A9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C43DA4F79044","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_91959D69DC35","predicate":"total_equity","value":"9,309,739,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 9,309,739,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_91959D69DC35, https://asof.is/claim/clm_91959D69DC35, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_91959D69DC35","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_85F66B9E6C53","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_97DAFF25A056","predicate":"research_and_development","value":"1,759,945,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 1,759,945,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_97DAFF25A056, https://asof.is/claim/clm_97DAFF25A056, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_97DAFF25A056","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A89347762D25","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_9F2904CE8D05","predicate":"net_income","value":"2,591,566,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 2,591,566,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_9F2904CE8D05, https://asof.is/claim/clm_9F2904CE8D05, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_9F2904CE8D05","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_97D551EB0FC8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_A7885EF38F91","predicate":"operating_income","value":"4,010,175,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-12-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 4,010,175,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_A7885EF38F91, https://asof.is/claim/clm_A7885EF38F91, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_A7885EF38F91","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BC08A5BEA713","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_FCBEE31BA577","predicate":"cash_and_equivalents","value":"1,803,694,000 United States dollar","valid_from":"2012-12-31","valid_to":"2013-03-31","published":"2013-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,803,694,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_FCBEE31BA577, https://asof.is/claim/clm_FCBEE31BA577, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm.","url":"https://asof.is/claim/clm_FCBEE31BA577","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3F890EF44E32","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2012","published_at":"2013-02-27T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-27"}},{"id":"clm_E031E45D588C","predicate":"shares_outstanding","value":"757,648,151 shares","valid_from":"2012-10-26","valid_to":"2013-02-15","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 757,648,151 shares\", as of 2012-10-26 (until 2013-02-15). Claim clm_E031E45D588C, https://asof.is/claim/clm_E031E45D588C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_E031E45D588C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_45B915515FE5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_5682E86D49EF","predicate":"quarterly_research_and_development","value":"465,831,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2013-10-31","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 465,831,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_5682E86D49EF, https://asof.is/claim/clm_5682E86D49EF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm.","url":"https://asof.is/claim/clm_5682E86D49EF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4716BEA47C18","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000046/0000882095-13-000046-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2013","published_at":"2013-10-31T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2013, filed 2013-10-31"}},{"id":"clm_6AA4CA365EAD","predicate":"total_assets","value":"20,963,829,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 20,963,829,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_6AA4CA365EAD, https://asof.is/claim/clm_6AA4CA365EAD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_6AA4CA365EAD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_15468AB110B1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_B643FBA97A26","predicate":"quarterly_net_income","value":"675,505,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 675,505,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_B643FBA97A26, https://asof.is/claim/clm_B643FBA97A26, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_B643FBA97A26","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_388E2FFF1D4B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_B8600EE329E3","predicate":"quarterly_revenue","value":"2,426,597,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,426,597,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_B8600EE329E3, https://asof.is/claim/clm_B8600EE329E3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_B8600EE329E3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_CF7263DF8433","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_E1F92FF8F547","predicate":"total_equity","value":"8,603,642,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 8,603,642,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_E1F92FF8F547, https://asof.is/claim/clm_E1F92FF8F547, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_E1F92FF8F547","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_91959D69DC35","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_F539577166A9","predicate":"cash_and_equivalents","value":"1,550,710,000 United States dollar","valid_from":"2012-09-30","valid_to":"2012-12-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,550,710,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_F539577166A9, https://asof.is/claim/clm_F539577166A9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_F539577166A9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FCBEE31BA577","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_FA96CB92CE64","predicate":"quarterly_operating_income","value":"1,043,914,000 United States dollar","valid_from":"2012-09-30","valid_to":"2013-03-31","published":"2012-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,043,914,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_FA96CB92CE64, https://asof.is/claim/clm_FA96CB92CE64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm.","url":"https://asof.is/claim/clm_FA96CB92CE64","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_4AB2B075DD45","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000029/0000882095-12-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2012","published_at":"2012-11-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-06"}},{"id":"clm_FDFFC4589CCA","predicate":"shares_outstanding","value":"756,568,507 shares","valid_from":"2012-07-20","valid_to":"2012-10-26","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 756,568,507 shares\", as of 2012-07-20 (until 2012-10-26). Claim clm_FDFFC4589CCA, https://asof.is/claim/clm_FDFFC4589CCA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_FDFFC4589CCA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E031E45D588C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_0819CD93D3BE","predicate":"cash_and_equivalents","value":"1,625,500,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,625,500,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_0819CD93D3BE, https://asof.is/claim/clm_0819CD93D3BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_0819CD93D3BE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F539577166A9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_35B1D94A76C2","predicate":"total_assets","value":"20,501,950,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 20,501,950,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_35B1D94A76C2, https://asof.is/claim/clm_35B1D94A76C2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_35B1D94A76C2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6AA4CA365EAD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_67DBD97EDB58","predicate":"total_equity","value":"8,002,120,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 8,002,120,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_67DBD97EDB58, https://asof.is/claim/clm_67DBD97EDB58, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_67DBD97EDB58","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E1F92FF8F547","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_74B44D14A03E","predicate":"quarterly_operating_income","value":"1,059,092,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,059,092,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_74B44D14A03E, https://asof.is/claim/clm_74B44D14A03E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_74B44D14A03E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FA96CB92CE64","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_D51703E0CC72","predicate":"quarterly_net_income","value":"706,074,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 706,074,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_D51703E0CC72, https://asof.is/claim/clm_D51703E0CC72, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_D51703E0CC72","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B643FBA97A26","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_DA658E3C399A","predicate":"quarterly_research_and_development","value":"396,244,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2013-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 396,244,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_DA658E3C399A, https://asof.is/claim/clm_DA658E3C399A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm.","url":"https://asof.is/claim/clm_DA658E3C399A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5682E86D49EF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000038/0000882095-13-000038-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2013","published_at":"2013-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q2 FY2013, filed 2013-08-01"}},{"id":"clm_FB8DA58174AA","predicate":"quarterly_revenue","value":"2,405,186,000 United States dollar","valid_from":"2012-06-30","valid_to":"2012-09-30","published":"2012-08-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,405,186,000 United States dollar\", as of 2012-06-30 (until 2012-09-30). Claim clm_FB8DA58174AA, https://asof.is/claim/clm_FB8DA58174AA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm.","url":"https://asof.is/claim/clm_FB8DA58174AA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B8600EE329E3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209512000013/0000882095-12-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2012","published_at":"2012-08-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2012, filed 2012-08-01"}},{"id":"clm_0D0B69B94297","predicate":"shares_outstanding","value":"757,321,824 shares","valid_from":"2012-04-27","valid_to":"2012-07-20","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 757,321,824 shares\", as of 2012-04-27 (until 2012-07-20). Claim clm_0D0B69B94297, https://asof.is/claim/clm_0D0B69B94297, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_0D0B69B94297","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FDFFC4589CCA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_1B04A7872EB1","predicate":"quarterly_operating_income","value":"800,186,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 800,186,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_1B04A7872EB1, https://asof.is/claim/clm_1B04A7872EB1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_1B04A7872EB1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_74B44D14A03E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_3E3CA2BE557A","predicate":"cash_and_equivalents","value":"1,451,942,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,451,942,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_3E3CA2BE557A, https://asof.is/claim/clm_3E3CA2BE557A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_3E3CA2BE557A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0819CD93D3BE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_5146FDD0A30B","predicate":"total_assets","value":"19,950,386,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 19,950,386,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_5146FDD0A30B, https://asof.is/claim/clm_5146FDD0A30B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_5146FDD0A30B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_35B1D94A76C2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_582F2BDA4127","predicate":"quarterly_research_and_development","value":"458,211,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2013-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 458,211,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_582F2BDA4127, https://asof.is/claim/clm_582F2BDA4127, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm.","url":"https://asof.is/claim/clm_582F2BDA4127","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DA658E3C399A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209513000029/0000882095-13-000029-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2013","published_at":"2013-05-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2013, filed 2013-05-08"}},{"id":"clm_EB005128324C","predicate":"quarterly_revenue","value":"2,282,449,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,282,449,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_EB005128324C, https://asof.is/claim/clm_EB005128324C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_EB005128324C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FB8DA58174AA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_F100EC2AA0AB","predicate":"total_equity","value":"7,313,612,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 7,313,612,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_F100EC2AA0AB, https://asof.is/claim/clm_F100EC2AA0AB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_F100EC2AA0AB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_67DBD97EDB58","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_F9773DDC0E63","predicate":"quarterly_net_income","value":"437,531,000 United States dollar","valid_from":"2012-03-31","valid_to":"2012-06-30","published":"2012-05-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 437,531,000 United States dollar\", as of 2012-03-31 (until 2012-06-30). Claim clm_F9773DDC0E63, https://asof.is/claim/clm_F9773DDC0E63, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm.","url":"https://asof.is/claim/clm_F9773DDC0E63","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D51703E0CC72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000144530512001487/0001445305-12-001487-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2012","published_at":"2012-05-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-04"}},{"id":"clm_BA2204982948","predicate":"shares_outstanding","value":"757,315,361 shares","valid_from":"2012-02-10","valid_to":"2012-04-27","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 757,315,361 shares\", as of 2012-02-10 (until 2012-04-27). Claim clm_BA2204982948, https://asof.is/claim/clm_BA2204982948, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_BA2204982948","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0D0B69B94297","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_019E95D10520","predicate":"total_equity","value":"6,738,856,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 6,738,856,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_019E95D10520, https://asof.is/claim/clm_019E95D10520, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_019E95D10520","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F100EC2AA0AB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_1CA54A90EE0E","predicate":"cash_and_equivalents","value":"9,883,777,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 9,883,777,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_1CA54A90EE0E, https://asof.is/claim/clm_1CA54A90EE0E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_1CA54A90EE0E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3E3CA2BE557A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_3C7AA6C6D6B9","predicate":"revenue","value":"8,385,385,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 8,385,385,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_3C7AA6C6D6B9, https://asof.is/claim/clm_3C7AA6C6D6B9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_3C7AA6C6D6B9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6D4418F572A9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_696C99F8BC73","predicate":"net_income","value":"2,803,637,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 2,803,637,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_696C99F8BC73, https://asof.is/claim/clm_696C99F8BC73, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_696C99F8BC73","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9F2904CE8D05","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_B88E927B540C","predicate":"total_assets","value":"17,303,134,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-03-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 17,303,134,000 United States dollar\", as of 2011-12-31 (until 2012-03-31). Claim clm_B88E927B540C, https://asof.is/claim/clm_B88E927B540C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_B88E927B540C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5146FDD0A30B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_BB578960787F","predicate":"operating_income","value":"3,789,841,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2012-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 3,789,841,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_BB578960787F, https://asof.is/claim/clm_BB578960787F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm.","url":"https://asof.is/claim/clm_BB578960787F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A7885EF38F91","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2011","published_at":"2012-02-23T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2011, filed 2012-02-23"}},{"id":"clm_CB687DD570D4","predicate":"research_and_development","value":"1,229,151,000 United States dollar","valid_from":"2011-12-31","valid_to":"2012-12-31","published":"2014-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 1,229,151,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_CB687DD570D4, https://asof.is/claim/clm_CB687DD570D4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm.","url":"https://asof.is/claim/clm_CB687DD570D4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_97DAFF25A056","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2013","published_at":"2014-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2013, filed 2014-02-25"}},{"id":"clm_6CB5D3B4BCE5","predicate":"shares_outstanding","value":"751,139,232 shares","valid_from":"2011-10-28","valid_to":"2012-02-10","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 751,139,232 shares\", as of 2011-10-28 (until 2012-02-10). Claim clm_6CB5D3B4BCE5, https://asof.is/claim/clm_6CB5D3B4BCE5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_6CB5D3B4BCE5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA2204982948","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_014BF0FFC36B","predicate":"quarterly_revenue","value":"2,121,660,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,121,660,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_014BF0FFC36B, https://asof.is/claim/clm_014BF0FFC36B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_014BF0FFC36B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EB005128324C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_3A732D3657F3","predicate":"quarterly_operating_income","value":"1,003,678,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,003,678,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_3A732D3657F3, https://asof.is/claim/clm_3A732D3657F3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_3A732D3657F3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1B04A7872EB1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_A15E593F7D06","predicate":"cash_and_equivalents","value":"909,359,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 909,359,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_A15E593F7D06, https://asof.is/claim/clm_A15E593F7D06, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_A15E593F7D06","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1CA54A90EE0E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_E02857054536","predicate":"total_equity","value":"6,116,764,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 6,116,764,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_E02857054536, https://asof.is/claim/clm_E02857054536, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_E02857054536","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_019E95D10520","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_E36AEE86C835","predicate":"quarterly_net_income","value":"741,124,000 United States dollar","valid_from":"2011-09-30","valid_to":"2012-03-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 741,124,000 United States dollar\", as of 2011-09-30 (until 2012-03-31). Claim clm_E36AEE86C835, https://asof.is/claim/clm_E36AEE86C835, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_E36AEE86C835","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F9773DDC0E63","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_F5164DFA9D86","predicate":"total_assets","value":"12,639,898,000 United States dollar","valid_from":"2011-09-30","valid_to":"2011-12-31","published":"2011-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 12,639,898,000 United States dollar\", as of 2011-09-30 (until 2011-12-31). Claim clm_F5164DFA9D86, https://asof.is/claim/clm_F5164DFA9D86, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm.","url":"https://asof.is/claim/clm_F5164DFA9D86","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B88E927B540C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511297580/0001193125-11-297580-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2011","published_at":"2011-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-11-04"}},{"id":"clm_16C8F46A3318","predicate":"shares_outstanding","value":"771,455,146 shares","valid_from":"2011-07-29","valid_to":"2011-10-28","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 771,455,146 shares\", as of 2011-07-29 (until 2011-10-28). Claim clm_16C8F46A3318, https://asof.is/claim/clm_16C8F46A3318, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_16C8F46A3318","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6CB5D3B4BCE5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_0A415A5A9101","predicate":"cash_and_equivalents","value":"905,779,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 905,779,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_0A415A5A9101, https://asof.is/claim/clm_0A415A5A9101, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_0A415A5A9101","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A15E593F7D06","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_0ECE630659F3","predicate":"quarterly_operating_income","value":"1,016,718,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,016,718,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_0ECE630659F3, https://asof.is/claim/clm_0ECE630659F3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_0ECE630659F3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3A732D3657F3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_13EE23B014A4","predicate":"total_assets","value":"12,694,140,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 12,694,140,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_13EE23B014A4, https://asof.is/claim/clm_13EE23B014A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_13EE23B014A4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F5164DFA9D86","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_25328C0EEB54","predicate":"quarterly_revenue","value":"2,137,253,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,137,253,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_25328C0EEB54, https://asof.is/claim/clm_25328C0EEB54, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_25328C0EEB54","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_014BF0FFC36B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_3834A1B5CB30","predicate":"total_equity","value":"6,046,845,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 6,046,845,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_3834A1B5CB30, https://asof.is/claim/clm_3834A1B5CB30, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_3834A1B5CB30","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E02857054536","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_701712B0358C","predicate":"quarterly_net_income","value":"746,227,000 United States dollar","valid_from":"2011-06-30","valid_to":"2011-09-30","published":"2011-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 746,227,000 United States dollar\", as of 2011-06-30 (until 2011-09-30). Claim clm_701712B0358C, https://asof.is/claim/clm_701712B0358C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm.","url":"https://asof.is/claim/clm_701712B0358C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E36AEE86C835","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511212453/0001193125-11-212453-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2011","published_at":"2011-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-05"}},{"id":"clm_945AE266BF3E","predicate":"shares_outstanding","value":"787,054,365 shares","valid_from":"2011-04-29","valid_to":"2011-07-29","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 787,054,365 shares\", as of 2011-04-29 (until 2011-07-29). Claim clm_945AE266BF3E, https://asof.is/claim/clm_945AE266BF3E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_945AE266BF3E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_16C8F46A3318","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_1391B52ED0E7","predicate":"quarterly_revenue","value":"1,926,094,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,926,094,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_1391B52ED0E7, https://asof.is/claim/clm_1391B52ED0E7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_1391B52ED0E7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_25328C0EEB54","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_37E625A398A2","predicate":"total_equity","value":"5,946,253,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 5,946,253,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_37E625A398A2, https://asof.is/claim/clm_37E625A398A2, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_37E625A398A2","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3834A1B5CB30","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_62BE5B94324C","predicate":"quarterly_operating_income","value":"901,969,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 901,969,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_62BE5B94324C, https://asof.is/claim/clm_62BE5B94324C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_62BE5B94324C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0ECE630659F3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_83C8E8B7607D","predicate":"total_assets","value":"12,987,354,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 12,987,354,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_83C8E8B7607D, https://asof.is/claim/clm_83C8E8B7607D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_83C8E8B7607D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_13EE23B014A4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_92A5B85265B5","predicate":"quarterly_net_income","value":"651,141,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 651,141,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_92A5B85265B5, https://asof.is/claim/clm_92A5B85265B5, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_92A5B85265B5","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_701712B0358C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_DA423A0F862C","predicate":"cash_and_equivalents","value":"1,835,978,000 United States dollar","valid_from":"2011-03-31","valid_to":"2011-06-30","published":"2011-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,835,978,000 United States dollar\", as of 2011-03-31 (until 2011-06-30). Claim clm_DA423A0F862C, https://asof.is/claim/clm_DA423A0F862C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm.","url":"https://asof.is/claim/clm_DA423A0F862C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0A415A5A9101","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511132405/0001193125-11-132405-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2011","published_at":"2011-05-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-09"}},{"id":"clm_38CA76B552E6","predicate":"shares_outstanding","value":"795,264,644 shares","valid_from":"2011-02-18","valid_to":"2011-04-29","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 795,264,644 shares\", as of 2011-02-18 (until 2011-04-29). Claim clm_38CA76B552E6, https://asof.is/claim/clm_38CA76B552E6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_38CA76B552E6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_945AE266BF3E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_2C4E606A042E","predicate":"operating_income","value":"3,962,222,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 3,962,222,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_2C4E606A042E, https://asof.is/claim/clm_2C4E606A042E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_2C4E606A042E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BB578960787F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_428390C0A446","predicate":"cash_and_equivalents","value":"907,879,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 907,879,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_428390C0A446, https://asof.is/claim/clm_428390C0A446, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_428390C0A446","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DA423A0F862C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_819CF52FBEB1","predicate":"revenue","value":"7,949,420,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 7,949,420,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_819CF52FBEB1, https://asof.is/claim/clm_819CF52FBEB1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_819CF52FBEB1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3C7AA6C6D6B9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_B3A3FCFB5B2E","predicate":"total_equity","value":"5,863,729,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 5,863,729,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_B3A3FCFB5B2E, https://asof.is/claim/clm_B3A3FCFB5B2E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_B3A3FCFB5B2E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_37E625A398A2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_F033D3C42EC9","predicate":"net_income","value":"2,901,257,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 2,901,257,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_F033D3C42EC9, https://asof.is/claim/clm_F033D3C42EC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_F033D3C42EC9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_696C99F8BC73","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_FF9FE6679302","predicate":"total_assets","value":"11,592,630,000 United States dollar","valid_from":"2010-12-31","valid_to":"2011-03-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 11,592,630,000 United States dollar\", as of 2010-12-31 (until 2011-03-31). Claim clm_FF9FE6679302, https://asof.is/claim/clm_FF9FE6679302, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm.","url":"https://asof.is/claim/clm_FF9FE6679302","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_83C8E8B7607D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2010","published_at":"2011-02-28T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-28"}},{"id":"clm_21239540FB7C","predicate":"shares_outstanding","value":"811,867,667 shares","valid_from":"2010-10-29","valid_to":"2011-02-18","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 811,867,667 shares\", as of 2010-10-29 (until 2011-02-18). Claim clm_21239540FB7C, https://asof.is/claim/clm_21239540FB7C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_21239540FB7C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_38CA76B552E6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_35B4BBB949FD","predicate":"total_assets","value":"11,455,591,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 11,455,591,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_35B4BBB949FD, https://asof.is/claim/clm_35B4BBB949FD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_35B4BBB949FD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FF9FE6679302","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_BA2733FE8D7B","predicate":"total_equity","value":"5,706,314,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 5,706,314,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_BA2733FE8D7B, https://asof.is/claim/clm_BA2733FE8D7B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_BA2733FE8D7B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B3A3FCFB5B2E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_D24119C16413","predicate":"quarterly_operating_income","value":"979,073,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 979,073,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_D24119C16413, https://asof.is/claim/clm_D24119C16413, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_D24119C16413","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_62BE5B94324C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_E81E791E414C","predicate":"quarterly_revenue","value":"1,937,656,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,937,656,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_E81E791E414C, https://asof.is/claim/clm_E81E791E414C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_E81E791E414C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1391B52ED0E7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_EC9A7EDCAE43","predicate":"cash_and_equivalents","value":"1,022,993,000 United States dollar","valid_from":"2010-09-30","valid_to":"2010-12-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,022,993,000 United States dollar\", as of 2010-09-30 (until 2010-12-31). Claim clm_EC9A7EDCAE43, https://asof.is/claim/clm_EC9A7EDCAE43, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_EC9A7EDCAE43","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_428390C0A446","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_EDF797644901","predicate":"quarterly_net_income","value":"704,876,000 United States dollar","valid_from":"2010-09-30","valid_to":"2011-03-31","published":"2010-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 704,876,000 United States dollar\", as of 2010-09-30 (until 2011-03-31). Claim clm_EDF797644901, https://asof.is/claim/clm_EDF797644901, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm.","url":"https://asof.is/claim/clm_EDF797644901","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_92A5B85265B5","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510252253/0001193125-10-252253-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2010","published_at":"2010-11-08T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-08"}},{"id":"clm_A22E6E059246","predicate":"shares_outstanding","value":"838,632,586 shares","valid_from":"2010-07-31","valid_to":"2010-10-29","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 838,632,586 shares\", as of 2010-07-31 (until 2010-10-29). Claim clm_A22E6E059246, https://asof.is/claim/clm_A22E6E059246, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_A22E6E059246","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_21239540FB7C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_1C850A47D02B","predicate":"cash_and_equivalents","value":"1,482,639,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,482,639,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_1C850A47D02B, https://asof.is/claim/clm_1C850A47D02B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_1C850A47D02B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EC9A7EDCAE43","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_48FDDE6A06BE","predicate":"total_assets","value":"10,496,708,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 10,496,708,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_48FDDE6A06BE, https://asof.is/claim/clm_48FDDE6A06BE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_48FDDE6A06BE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_35B4BBB949FD","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_5442C3CA182A","predicate":"quarterly_revenue","value":"1,927,224,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,927,224,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_5442C3CA182A, https://asof.is/claim/clm_5442C3CA182A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_5442C3CA182A","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E81E791E414C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_60B45A77886C","predicate":"quarterly_net_income","value":"712,061,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 712,061,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_60B45A77886C, https://asof.is/claim/clm_60B45A77886C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_60B45A77886C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EDF797644901","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_7D72B6AC9B7E","predicate":"total_equity","value":"6,562,495,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 6,562,495,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_7D72B6AC9B7E, https://asof.is/claim/clm_7D72B6AC9B7E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_7D72B6AC9B7E","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA2733FE8D7B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_DB4269EFC676","predicate":"quarterly_operating_income","value":"992,627,000 United States dollar","valid_from":"2010-06-30","valid_to":"2010-09-30","published":"2010-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 992,627,000 United States dollar\", as of 2010-06-30 (until 2010-09-30). Claim clm_DB4269EFC676, https://asof.is/claim/clm_DB4269EFC676, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm.","url":"https://asof.is/claim/clm_DB4269EFC676","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D24119C16413","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510182351/0001193125-10-182351-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2010","published_at":"2010-08-09T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-09"}},{"id":"clm_0EFC19D5D09D","predicate":"shares_outstanding","value":"889,915,070 shares","valid_from":"2010-04-30","valid_to":"2010-07-31","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 889,915,070 shares\", as of 2010-04-30 (until 2010-07-31). Claim clm_0EFC19D5D09D, https://asof.is/claim/clm_0EFC19D5D09D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_0EFC19D5D09D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A22E6E059246","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_1164210268A4","predicate":"cash_and_equivalents","value":"936,880,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 936,880,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_1164210268A4, https://asof.is/claim/clm_1164210268A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_1164210268A4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1C850A47D02B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_179B9A3F4355","predicate":"quarterly_net_income","value":"854,901,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 854,901,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_179B9A3F4355, https://asof.is/claim/clm_179B9A3F4355, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_179B9A3F4355","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_60B45A77886C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_25260B33C1B4","predicate":"total_assets","value":"10,695,998,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 10,695,998,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_25260B33C1B4, https://asof.is/claim/clm_25260B33C1B4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_25260B33C1B4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_48FDDE6A06BE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_94692F85C62C","predicate":"quarterly_revenue","value":"2,085,853,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 2,085,853,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_94692F85C62C, https://asof.is/claim/clm_94692F85C62C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_94692F85C62C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_5442C3CA182A","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_B1C0CFC36770","predicate":"total_equity","value":"7,341,996,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 7,341,996,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_B1C0CFC36770, https://asof.is/claim/clm_B1C0CFC36770, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_B1C0CFC36770","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7D72B6AC9B7E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_FF1303054202","predicate":"quarterly_operating_income","value":"1,161,141,000 United States dollar","valid_from":"2010-03-31","valid_to":"2010-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 1,161,141,000 United States dollar\", as of 2010-03-31 (until 2010-06-30). Claim clm_FF1303054202, https://asof.is/claim/clm_FF1303054202, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_FF1303054202","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DB4269EFC676","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_8CAAAB1E52C8","predicate":"shares_outstanding","value":"903,378,986 shares","valid_from":"2010-02-19","valid_to":"2010-04-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 903,378,986 shares\", as of 2010-02-19 (until 2010-04-30). Claim clm_8CAAAB1E52C8, https://asof.is/claim/clm_8CAAAB1E52C8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_8CAAAB1E52C8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0EFC19D5D09D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_17191420B94F","predicate":"cash_and_equivalents","value":"1,272,958,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,272,958,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_17191420B94F, https://asof.is/claim/clm_17191420B94F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_17191420B94F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1164210268A4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_23ACEDC261B0","predicate":"revenue","value":"7,011,383,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 7,011,383,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_23ACEDC261B0, https://asof.is/claim/clm_23ACEDC261B0, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_23ACEDC261B0","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_819CF52FBEB1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_3163182F8E92","predicate":"total_equity","value":"6,367,065,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 6,367,065,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_3163182F8E92, https://asof.is/claim/clm_3163182F8E92, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_3163182F8E92","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B1C0CFC36770","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_78A0730C637B","predicate":"total_assets","value":"9,698,559,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 9,698,559,000 United States dollar\", as of 2009-12-31 (until 2010-03-31). Claim clm_78A0730C637B, https://asof.is/claim/clm_78A0730C637B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_78A0730C637B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_25260B33C1B4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_C3B225B42864","predicate":"net_income","value":"2,635,755,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 2,635,755,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_C3B225B42864, https://asof.is/claim/clm_C3B225B42864, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_C3B225B42864","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F033D3C42EC9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_C64800E0E7CB","predicate":"operating_income","value":"3,529,221,000 United States dollar","valid_from":"2009-12-31","valid_to":"2010-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 3,529,221,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_C64800E0E7CB, https://asof.is/claim/clm_C64800E0E7CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_C64800E0E7CB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_2C4E606A042E","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_E6FBDCCF9039","predicate":"shares_outstanding","value":"899,925,051 shares","valid_from":"2009-10-30","valid_to":"2010-02-19","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 899,925,051 shares\", as of 2009-10-30 (until 2010-02-19). Claim clm_E6FBDCCF9039, https://asof.is/claim/clm_E6FBDCCF9039, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_E6FBDCCF9039","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8CAAAB1E52C8","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_1DD26E92789F","predicate":"cash_and_equivalents","value":"1,024,599,000 United States dollar","valid_from":"2009-09-30","valid_to":"2009-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,024,599,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_1DD26E92789F, https://asof.is/claim/clm_1DD26E92789F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_1DD26E92789F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_17191420B94F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_6A5B983F30CE","predicate":"quarterly_revenue","value":"1,801,389,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,801,389,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_6A5B983F30CE, https://asof.is/claim/clm_6A5B983F30CE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_6A5B983F30CE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_94692F85C62C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_814FA38F27EA","predicate":"total_equity","value":"5,646,538,000 United States dollar","valid_from":"2009-09-30","valid_to":"2009-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 5,646,538,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_814FA38F27EA, https://asof.is/claim/clm_814FA38F27EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_814FA38F27EA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3163182F8E92","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_E5F680B5FF62","predicate":"quarterly_net_income","value":"673,033,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 673,033,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_E5F680B5FF62, https://asof.is/claim/clm_E5F680B5FF62, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_E5F680B5FF62","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_179B9A3F4355","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_E64B83E77382","predicate":"total_assets","value":"8,936,980,000 United States dollar","valid_from":"2009-09-30","valid_to":"2009-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 8,936,980,000 United States dollar\", as of 2009-09-30 (until 2009-12-31). Claim clm_E64B83E77382, https://asof.is/claim/clm_E64B83E77382, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_E64B83E77382","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78A0730C637B","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_FC1BDAE84C91","predicate":"quarterly_operating_income","value":"894,406,000 United States dollar","valid_from":"2009-09-30","valid_to":"2010-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 894,406,000 United States dollar\", as of 2009-09-30 (until 2010-03-31). Claim clm_FC1BDAE84C91, https://asof.is/claim/clm_FC1BDAE84C91, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_FC1BDAE84C91","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FF1303054202","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_F2F37AF506D8","predicate":"shares_outstanding","value":"904,261,310 shares","valid_from":"2009-07-31","valid_to":"2009-10-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 904,261,310 shares\", as of 2009-07-31 (until 2009-10-30). Claim clm_F2F37AF506D8, https://asof.is/claim/clm_F2F37AF506D8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_F2F37AF506D8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E6FBDCCF9039","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_1F54E418D5B7","predicate":"quarterly_operating_income","value":"761,061,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 761,061,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_1F54E418D5B7, https://asof.is/claim/clm_1F54E418D5B7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_1F54E418D5B7","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FC1BDAE84C91","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_409B6A3263EA","predicate":"quarterly_revenue","value":"1,647,155,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,647,155,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_409B6A3263EA, https://asof.is/claim/clm_409B6A3263EA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_409B6A3263EA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6A5B983F30CE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_695C397CCD54","predicate":"quarterly_net_income","value":"571,398,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 571,398,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_695C397CCD54, https://asof.is/claim/clm_695C397CCD54, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_695C397CCD54","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E5F680B5FF62","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_912C3B816D46","predicate":"total_equity","value":"5,189,851,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 5,189,851,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_912C3B816D46, https://asof.is/claim/clm_912C3B816D46, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_912C3B816D46","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_814FA38F27EA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_9B0E04E191E1","predicate":"total_assets","value":"8,387,092,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 8,387,092,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_9B0E04E191E1, https://asof.is/claim/clm_9B0E04E191E1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_9B0E04E191E1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_E64B83E77382","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_BBB5026F2E31","predicate":"cash_and_equivalents","value":"1,040,874,000 United States dollar","valid_from":"2009-06-30","valid_to":"2009-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,040,874,000 United States dollar\", as of 2009-06-30 (until 2009-09-30). Claim clm_BBB5026F2E31, https://asof.is/claim/clm_BBB5026F2E31, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_BBB5026F2E31","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1DD26E92789F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_56A15A606CEF","predicate":"cash_and_equivalents","value":"1,663,646,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,663,646,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_56A15A606CEF, https://asof.is/claim/clm_56A15A606CEF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_56A15A606CEF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BBB5026F2E31","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_6B051E490584","predicate":"quarterly_net_income","value":"589,112,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 589,112,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_6B051E490584, https://asof.is/claim/clm_6B051E490584, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_6B051E490584","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_695C397CCD54","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_6C439F1205CB","predicate":"quarterly_revenue","value":"1,530,460,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,530,460,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_6C439F1205CB, https://asof.is/claim/clm_6C439F1205CB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_6C439F1205CB","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_409B6A3263EA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_D580476ACDEA","predicate":"quarterly_operating_income","value":"808,316,000 United States dollar","valid_from":"2009-03-31","valid_to":"2009-06-30","published":"2010-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 808,316,000 United States dollar\", as of 2009-03-31 (until 2009-06-30). Claim clm_D580476ACDEA, https://asof.is/claim/clm_D580476ACDEA, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm.","url":"https://asof.is/claim/clm_D580476ACDEA","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1F54E418D5B7","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510114616/0001193125-10-114616-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2010","published_at":"2010-05-10T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-10"}},{"id":"clm_02B160679CDF","predicate":"total_equity","value":"4,272,573,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 4,272,573,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_02B160679CDF, https://asof.is/claim/clm_02B160679CDF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_02B160679CDF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_912C3B816D46","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_090DE766E964","predicate":"operating_income","value":"2,678,541,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 2,678,541,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_090DE766E964, https://asof.is/claim/clm_090DE766E964, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_090DE766E964","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C64800E0E7CB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_35D02F2808B3","predicate":"net_income","value":"1,978,899,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 1,978,899,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_35D02F2808B3, https://asof.is/claim/clm_35D02F2808B3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_35D02F2808B3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C3B225B42864","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_78AFDF7AC308","predicate":"revenue","value":"5,335,750,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 5,335,750,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_78AFDF7AC308, https://asof.is/claim/clm_78AFDF7AC308, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_78AFDF7AC308","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_23ACEDC261B0","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_A15E9B5FEB96","predicate":"cash_and_equivalents","value":"1,459,302,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-03-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,459,302,000 United States dollar\", as of 2008-12-31 (until 2009-03-31). Claim clm_A15E9B5FEB96, https://asof.is/claim/clm_A15E9B5FEB96, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_A15E9B5FEB96","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_56A15A606CEF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_E3E637C171EE","predicate":"total_assets","value":"6,936,831,000 United States dollar","valid_from":"2008-12-31","valid_to":"2009-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 6,936,831,000 United States dollar\", as of 2008-12-31 (until 2009-06-30). Claim clm_E3E637C171EE, https://asof.is/claim/clm_E3E637C171EE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_E3E637C171EE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9B0E04E191E1","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_558B16EA5C7C","predicate":"quarterly_net_income","value":"495,853,000 United States dollar","valid_from":"2008-09-30","valid_to":"2009-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 495,853,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_558B16EA5C7C, https://asof.is/claim/clm_558B16EA5C7C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_558B16EA5C7C","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6B051E490584","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_71CF9DEE2C5F","predicate":"cash_and_equivalents","value":"1,209,424,000 United States dollar","valid_from":"2008-09-30","valid_to":"2008-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,209,424,000 United States dollar\", as of 2008-09-30 (until 2008-12-31). Claim clm_71CF9DEE2C5F, https://asof.is/claim/clm_71CF9DEE2C5F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_71CF9DEE2C5F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_A15E9B5FEB96","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_7989DECF12D6","predicate":"quarterly_operating_income","value":"693,834,000 United States dollar","valid_from":"2008-09-30","valid_to":"2009-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 693,834,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_7989DECF12D6, https://asof.is/claim/clm_7989DECF12D6, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_7989DECF12D6","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D580476ACDEA","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_B6FDE1DA7495","predicate":"quarterly_revenue","value":"1,371,268,000 United States dollar","valid_from":"2008-09-30","valid_to":"2009-03-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,371,268,000 United States dollar\", as of 2008-09-30 (until 2009-03-31). Claim clm_B6FDE1DA7495, https://asof.is/claim/clm_B6FDE1DA7495, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm.","url":"https://asof.is/claim/clm_B6FDE1DA7495","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_6C439F1205CB","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509225660/0001193125-09-225660-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2009","published_at":"2009-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2009, filed 2009-11-05"}},{"id":"clm_226CF11D49AD","predicate":"quarterly_revenue","value":"1,278,125,000 United States dollar","valid_from":"2008-06-30","valid_to":"2008-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 1,278,125,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_226CF11D49AD, https://asof.is/claim/clm_226CF11D49AD, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_226CF11D49AD","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B6FDE1DA7495","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_AF94D3CB0BC1","predicate":"quarterly_operating_income","value":"605,515,000 United States dollar","valid_from":"2008-06-30","valid_to":"2008-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 605,515,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_AF94D3CB0BC1, https://asof.is/claim/clm_AF94D3CB0BC1, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_AF94D3CB0BC1","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7989DECF12D6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_F1BABC75C9BC","predicate":"quarterly_net_income","value":"434,783,000 United States dollar","valid_from":"2008-06-30","valid_to":"2008-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 434,783,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_F1BABC75C9BC, https://asof.is/claim/clm_F1BABC75C9BC, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_F1BABC75C9BC","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_558B16EA5C7C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_FCE3CE1DC9A4","predicate":"cash_and_equivalents","value":"1,119,599,000 United States dollar","valid_from":"2008-06-30","valid_to":"2008-09-30","published":"2009-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 1,119,599,000 United States dollar\", as of 2008-06-30 (until 2008-09-30). Claim clm_FCE3CE1DC9A4, https://asof.is/claim/clm_FCE3CE1DC9A4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm.","url":"https://asof.is/claim/clm_FCE3CE1DC9A4","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_71CF9DEE2C5F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312509165506/0001193125-09-165506-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q2 FY2009","published_at":"2009-08-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-05"}},{"id":"clm_2896D3FD1A51","predicate":"revenue","value":"4,230,045,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 4,230,045,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_2896D3FD1A51, https://asof.is/claim/clm_2896D3FD1A51, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_2896D3FD1A51","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_78AFDF7AC308","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_9D59E814F648","predicate":"cash_and_equivalents","value":"968,086,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-06-30","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 968,086,000 United States dollar\", as of 2007-12-31 (until 2008-06-30). Claim clm_9D59E814F648, https://asof.is/claim/clm_9D59E814F648, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_9D59E814F648","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_FCE3CE1DC9A4","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_9F8A791EDBD9","predicate":"net_income","value":"1,584,902,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 1,584,902,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_9F8A791EDBD9, https://asof.is/claim/clm_9F8A791EDBD9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_9F8A791EDBD9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_35D02F2808B3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_BF1309BFEE2D","predicate":"total_equity","value":"3,752,630,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 3,752,630,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_BF1309BFEE2D, https://asof.is/claim/clm_BF1309BFEE2D, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_BF1309BFEE2D","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_02B160679CDF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_C1A5FF719A45","predicate":"operating_income","value":"2,164,507,000 United States dollar","valid_from":"2007-12-31","valid_to":"2008-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 2,164,507,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_C1A5FF719A45, https://asof.is/claim/clm_C1A5FF719A45, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_C1A5FF719A45","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_090DE766E964","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_616F12FEE3F3","predicate":"total_equity","value":"2,051,546,000 United States dollar","valid_from":"2006-12-31","valid_to":"2007-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 2,051,546,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_616F12FEE3F3, https://asof.is/claim/clm_616F12FEE3F3, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_616F12FEE3F3","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BF1309BFEE2D","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_7743456F80CE","predicate":"cash_and_equivalents","value":"816,007,000 United States dollar","valid_from":"2006-12-31","valid_to":"2007-12-31","published":"2010-03-01","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 816,007,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_7743456F80CE, https://asof.is/claim/clm_7743456F80CE, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm.","url":"https://asof.is/claim/clm_7743456F80CE","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_9D59E814F648","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2009","published_at":"2010-03-01T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-03-01"}},{"id":"clm_B758636654A0","predicate":"registrant_name","value":"GILEAD SCIENCES, INC.","valid_from":"1994-02-14","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences registrant name: GILEAD SCIENCES, INC.\", as of 1994-02-14. Claim clm_B758636654A0, https://asof.is/claim/clm_B758636654A0, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_B758636654A0","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_6FC170F46335","predicate":"website","value":"https://www.gilead.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences website: https://www.gilead.com/\", undated. Claim clm_6FC170F46335, https://asof.is/claim/clm_6FC170F46335, accessed 2026-11-08. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_6FC170F46335","accessed":"2026-11-08"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Gilead Sciences.","url":"https://www.gilead.com/"}},{"id":"clm_3A93D2D56CBA","predicate":"cik","value":"0000882095","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cik: 0000882095\", undated. Claim clm_3A93D2D56CBA, https://asof.is/claim/clm_3A93D2D56CBA, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_3A93D2D56CBA","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_3AA77CFFBA18","predicate":"headquarters","value":"Foster City","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences headquarters: Foster City\", undated. Claim clm_3AA77CFFBA18, https://asof.is/claim/clm_3AA77CFFBA18, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_3AA77CFFBA18","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433BC2407C2F","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences state of incorporation: DE\", undated. Claim clm_433BC2407C2F, https://asof.is/claim/clm_433BC2407C2F, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_433BC2407C2F","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_44B0DF6C61E1","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_44B0DF6C61E1, https://asof.is/claim/clm_44B0DF6C61E1, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_44B0DF6C61E1","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_58190642DD33","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences fiscal year end: 12-31\", undated. Claim clm_58190642DD33, https://asof.is/claim/clm_58190642DD33, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_58190642DD33","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_79DB7756109C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences listed on: Nasdaq\", undated. Claim clm_79DB7756109C, https://asof.is/claim/clm_79DB7756109C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_79DB7756109C","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ACCCAF058EE1","predicate":"ticker","value":"GILD","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences ticker: GILD\", undated. Claim clm_ACCCAF058EE1, https://asof.is/claim/clm_ACCCAF058EE1, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_ACCCAF058EE1","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at."},"checked_by":{"sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}